



LucidQuest Intelligence
Accelerate your success



DDW2026
Digestive Disease Week®
MAY 2-5, 2026 | CHICAGO, IL
EXHIBIT DATES: MAY 3-5, 2026



DDW 2026 – General Overview

- ➔ • **Therapeutic Expansion:** DDW 2026 will showcase broad treatment innovation across IBD, MASLD, GERD, gastroparesis, pancreaticobiliary disease, and GI oncology
- ➔ • **Endoscopy-Led Care:** Advanced endoscopy is set to remain central, with EUS, ERCP, ESD, EMR, POEM, and bariatric endoscopy driving procedural evolution
- ➔ • **Inflammation Focus:** IBD data will emphasize IL-23, TL1A, anti-TNF, JAK, microbiome-based therapies, and biomarker-driven precision monitoring approaches
- ➔ • **Metabolic Liver Momentum:** MASLD and MASH studies are expected to highlight incretin-based therapies, resmetirom, fibrosis screening, and real-world safety
- ➔ • **Cancer Detection Priority:** GI oncology research will focus on early detection, Barrett's surveillance, colorectal cancer screening, pancreatic risk stratification, and molecular diagnostics
- ➔ • **Patient-Centered Outcomes:** The meeting is likely to feature stronger attention to symptoms, quality of life, access disparities, safety, and care pathway optimization



DDW 2026– Conference Themes (1/2)

- **IBD Precision Treatment:** IL-23, TL1A, ustekinumab, risankizumab, mirikizumab, and microbiota strategies are positioned to refine induction, maintenance, and postoperative monitoring
- **MASLD Treatment Differentiation:** Resmetirom, semaglutide, tirzepatide, SGLT2 inhibitors, and dietary interventions are expected to define comparative liver and metabolic benefit
- **Endoscopic Innovation:** EUS-guided drainage, ESD, EMR, POEM, LAMS, ESG, and duodenal mucosal ablation are poised to expand minimally invasive treatment options
- **Functional GI Advancement:** IBS, dyspepsia, fecal incontinence, GERD, achalasia, and gastroparesis studies are set to test neuromodulation, diet, probiotics, FMT, and device-based care





DDW 2026– Conference Themes (2/2)

- **AI and Biomarker Integration:** Machine learning, LLMs, fecal calprotectin assays, breath metabolites, cfDNA, and imaging biomarkers may improve diagnosis, triage, and monitoring
- **Equity and Safety:** Safety-net cohorts, pregnancy, older adults, cirrhosis, anticoagulation, endoscope reprocessing, and procedural risk studies are expected to sharpen real-world decision-making
- **Pancreatic & Biliary Innovation:** Early detection, cyst risk stratification, EUS-guided interventions, stenting strategies, and pancreatitis prevention approaches are expected to refine outcomes in high-mortality hepatopancreatobiliary diseases
- **Microbiome & Immune Modulation:** FMT, probiotics, engineered microbiota, and host–microbe interactions are likely to reshape treatment paradigms across IBD, IBS, MASLD, and GI oncology through targeted immune regulation



Noteworthy Scientific Presentations at DDW 2026





Key Topics From Notable Presentations (1/3)

- ✓ • **Inflammatory Bowel Disease (IBD):** ANTHEM-UC, VIVID-2, LUCENT, and ASPIRE-CD will reinforce IL-23 dominance, while Phase 2 TL1A data (tulisokibart) will expand fibrosis targeting. TRIUMPH-UC and biomarker studies will refine monitoring, with MIRO and de-escalation trials advancing microbiome and remission durability strategies
- ✓ • **Endoscopy & Advanced Therapeutics:** Multicenter RCTs in CAD colonoscopy and ACOSER will enhance detection and resection precision. Comparative trials on suturing, clipping, and sedation (RECOVER) will optimize safety, while LAMS and ESG meta-analyses will expand minimally invasive therapeutic boundaries
- ✓ • **Pancreatic & Biliary Diseases:** CERES-BILAT and CHOICE trials will redefine ERCP strategies, while RFA, radionuclide therapy, and anti-migratory stents will improve malignancy management. Large cohorts (~500,000 UK Biobank) will link pancreatitis to diabetes, reinforcing systemic disease implications



Key Topics From Notable Presentations (2/3)

- ✓ **GI Oncology & Premalignant Disease:** ESOPEC validation, BAMBI cfDNA, and Barrett's registry data will strengthen **early detection and surveillance**. Anti-PD-1 synergy studies and panitumumab meta-analysis (21% risk reduction) will refine **systemic therapy**, while **microbiome-driven tumor modulation** will emerge
- ✓ **Hepatology & Liver Disease:** MASLD trials comparing **semaglutide, tirzepatide, and resmetirom** will define **treatment hierarchy**. Propensity-matched cohorts (>10,000 patients) will refine cirrhosis outcomes, while screening gaps and elastography programs will reshape **population-level liver disease detection**
- ✓ **Functional GI Disorders & Motility:** FMT-FD, TRIUMPH IBS, and multiple RCTs (peppermint oil, electroacupuncture, hypnotherapy apps) will advance **gut-brain modulation**. Low-FODMAP and microbiota-targeted interventions will demonstrate **symptom control**, while POEM comparative trials will refine **motility disorder management**



Key Topics From Notable Presentations (3/3)

- ✓ • **Microbiome, Immunology & Translational Science:** CDI-SCOPE Phase 3B and MIRO trials will validate **microbiota therapeutics**, while antigen-specific immunotherapy and cytokine-targeting strategies will expand **immune modulation**. Multi-omics and microbial oncology studies will link microbiota to **treatment response and carcinogenesis**
- ✓ • **Upper GI, GERD & Esophageal Disorders:** TRIUMPH and REMODEL trials will advance **PCABs and biologics** in GERD and EoE, while **RESOLVE Phase 1B/2** will optimize dosing strategies. POEM RCTs and TIF registries will strengthen procedural innovation and **long-term reflux control**
- ✓ • **Obesity, Nutrition & Surgical Innovation:** Network meta-analyses will position **ESG alongside GLP-1 therapies**, while cost-effectiveness studies will compare mucosal ablation versus semaglutide. Combination therapy trials and bariatric outcomes will redefine integrated **metabolic care strategies**



Focus of Key Industry-Sponsored Sessions at DDW 2026 (1/2)

- **Key Focus Area 1: IBD Durable Control:**

- Sessions will highlight durable IBD outcomes, early advanced therapy, treatment goals, and patient-centered decisions

- **Key Focus Area 2: TL1A and Immuno-Fibrotic IBD:**

- Discussions will explore TL1A inhibition, inflammation–fibrosis biology, and emerging disease-modifying approaches in IBD

- **Key Focus Area 3: IL-23 and Subcutaneous IBD Therapies:**

- Presentations will cover IL-23p19 evidence, self-administered biologics, patient selection, and practical treatment optimization

- **Key Focus Area 4: Eosinophilic Esophagitis:**

- Sessions will focus on epithelial cytokines, diagnostic challenges, real-world cases, and evolving targeted EoE therapies



Focus of Key Industry-Sponsored Sessions at DDW 2026 (2/2)

- **Key Focus Area 5: Hepatology and Cholestatic Disease:**

- Discussions will cover PBC, HBV, MASH-directed therapy, hepatic encephalopathy, and case-based liver disease management

- **Key Focus Area 6: IBS-C and Gut–Brain Disorders:**

- Presentations will address symptom recognition, real-world IBS-C management, patient voices, and challenging clinical cases

- **Key Focus Area 7: Nutrition and Malabsorption:**

- Sessions will highlight short bowel syndrome, intestinal failure, EPI diagnosis, and multidisciplinary nutritional care

- **Key Focus Area 8: Precision Diagnostics:**

- Discussions will explore endohepatology imaging, elastography, Barrett's risk stratification, and precision clinical management



Notable Presentations And Late-breaking Sessions At DDW 2026

Notable Presentations Information At DDW 2026

Inflammatory Bowel Disease (1/4)



Date	Title
02 May 2026	<u>ICOTROKINRA, THE FIRST TARGETED ORAL PEPTIDE THAT SELECTIVELY BLOCKS THE INTERLEUKIN-23 RECEPTOR, REDUCES SYSTEMIC AND TISSUE INFLAMMATORY BURDEN IN ULCERATIVE COLITIS: RESULTS FROM THE ANTHEM-UC STUDY</u>
02 May 2026	<u>THE ANTI-TL1A MONOCLONAL ANTIBODY TULISOKIBART INHIBITS INFLAMMATORY AND FIBROSIS PATHWAYS: RESULTS FROM A PHASE 2 ULCERATIVE COLITIS STUDY</u>
02 May 2026	<u>MIRIKIZUMAB LONG-TERM SAFETY IN IBD: INTEGRATED ANALYSIS OF THE UC AND CD PHASE 3 STUDIES</u>
02 May 2026	<u>REAL-WORLD EFFECTIVENESS & SAFETY OF RISANKIZUMAB INDUCTION AND MAINTENANCE THERAPY IN PEDIATRIC PATIENTS WITH CROHN'S DISEASE: A MULTICENTER RETROSPECTIVE ANALYSIS</u>
02 May 2026	<u>TEMPORAL TRENDS IN CORTICOSTEROID USE AND HOSPITALIZATION IN ULCERATIVE COLITIS: RESULTS FROM A LONGITUDINAL POPULATION-BASED COHORT FROM 1970-2019</u>
02 May 2026	<u>EVOLUTION OF THE IBD-DISABILITY INDEX IN A COHORT OF RECENTLY DIAGNOSED CD PATIENTS: RESULTS FROM THE PROSPECTIVE CROCO (CROHN S DISEASE COHORT) STUDY</u>
02 May 2026	<u>MIRIKIZUMAB DEMONSTRATED LONG-TERM EFFICACY AND FAVORABLE SAFETY IN WEEK 52 ENDOSCOPIC NON-RESPONDERS WITH CROHN'S DISEASE: 3-YEAR VIVID-2 OPEN-LABEL EXTENSION INTERIM RESULTS</u>
02 May 2026	<u>MIRIKIZUMAB TREATMENT DECREASES ULCERATIVE COLITIS-RELATED SURGERY AND HOSPITALIZATION RATES: 4-YEAR LUCENT STUDIES RESULTS</u>

Notable Presentations Information At DDW 2026

Inflammatory Bowel Disease (2/4)



Date	Title
02 May 2026	<u>RISANKIZUMAB REDUCES CROHN'S DISEASE-RELATED SYMPTOMS AND CONCOMITANT THERAPY USE IN ADULTS WITH CROHN'S DISEASE: YEAR 1 RESULTS FROM THE ASPIRE-CD STUDY</u>
02 May 2026	<u>OPTIMIZING ULCERATIVE COLITIS MAINTENANCE TREATMENT: INDIRECT COMPARISON ON NUMBER NEEDED TO TREAT AMONG INTERLEUKIN-23P19 INHIBITORS HIGHLIGHTS MIRIKIZUMAB'S EFFICACY</u>
02 May 2026	<u>EFFECTIVENESS AND SAFETY OF GLP-1 RECEPTOR AGONISTS IN REDUCING OSTOMY OUTPUT AMONG IBD PATIENTS WITH ILEOSTOMIES</u>
02 May 2026	<u>HIGH PREVALENCE OF BOWEL URGENCY ACROSS IBD PATIENTS WITH AND WITHOUT REMISSION: RESULTS FROM A LARGE, PROSPECTIVE MULTICENTER COHORT</u>
02 May 2026	<u>IMMUNE TOXICITIES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES RECEIVING IMMUNE CHECKPOINT INHIBITORS: A SUBTYPE-BASED ANALYSIS COMPARING ULCERATIVE COLITIS AND CROHN'S DISEASE</u>
02 May 2026	<u>EFFICACY OF COMPOSITE SERUM BIOMARKERS IN POSTOPERATIVE CROHN'S DISEASE MONITORING</u>
02 May 2026	<u>ABDOMINAL ULTRASOUND COMBINED WITH SERUM C-REACTIVE PROTEIN AND FECAL CALPROTECTIN TO PREDICT THE EFFICACY OF USTEKINUMAB IN THE TREATMENT OF ACTIVE CROHN'S DISEASE</u>
02 May 2026	<u>PREDICTIVE VALUE OF CRP, ALBUMIN AND ABDOMINAL ULTRASOUND ELASTOGRAPHY TECHNOLOGY ON EFFICACY OF ANTI-TUMOR NECROSIS FACTOR-? MONOCLONAL ANTIBODIES IN PATIENTS WITH ACTIVE CROHN'S DISEASE</u>

Notable Presentations Information At DDW 2026

Inflammatory Bowel Disease (3/4)



Date	Title
02 May 2026	<u>COMPARING DIAGNOSTIC ACCURACY OF TRANSPERINEAL ULTRASOUND USING MICROCONVEX PROBE VERSUS CONVENTIONAL LINEAR PROBE TO PREDICT RECTAL HISTOENDOSCOPIC ACTIVITY IN ULCERATIVE COLITIS (TRIUMPH-UC): A PAIRED PROSPECTIVE, HEAD-TO-HEAD COMPARATIVE STUDY</u>
02 May 2026	<u>OVERCOMING TRANSLATIONAL GAPS IN IBD DRUG DISCOVERY WITH NEXT-GENERATION ANIMAL-FREE EFFICACY TESTING USING HUMAN-DERIVED IN VITRO INTESTINAL MODELS</u>
02 May 2026	<u>ASSESSING INTESTINAL PERMEABILITY IN ULCERATIVE COLITIS: RESULTS FROM A PILOT STUDY</u>
02 May 2026	<u>EFFICACY AND SAFETY OF BRIVEKIMIG (A DUAL-TARGET, ANTI-TUMOUR NECROSIS FACTOR AND ANTI-OX40 LIGAND NANOBODY®) IN PARTICIPANTS WITH MODERATE-TO-SEVERE HIDRADENITIS SUPPURATIVA: IMPLICATIONS FOR INFLAMMATORY BOWEL DISEASES</u>
02 May 2026	<u>TRANSPERINEAL ULTRASOUND VS MRI IN PERIANAL CROHN'S DISEASE: A VALIDATED SCORE COMPARISON</u>
02 May 2026	<u>VULNERABLE PHASES OF CARE FOR VENOUS THROMBOEMBOLIC EVENTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE</u>
02 May 2026	<u>BIOLOGICS AND SMALL MOLECULES FOR PERIANAL CROHN'S DISEASE: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSES OF RANDOMIZED PLACEBO-CONTROLLED TRIALS</u>
02 May 2026	<u>THE COMPARATIVE EFFICACY OF MEDICAL THERAPIES FOR INDUCTION OF REMISSION IN CHRONIC POUCHITIS: SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS</u>

Notable Presentations Information At DDW 2026

Inflammatory Bowel Disease (4/4)



Date	Title
02 May 2026	<u>CLINICAL EFFICACY OF USTEKINUMAB IN THE MANAGEMENT OF CHRONIC POUCHITIS: SYSTEMATIC REVIEW AND META-ANALYSIS</u>
02 May 2026	<u>EFFICACY AND SAFETY OF FECAL MICROBIOTA TRANSPLANTATION IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH RECURRENT CLOSTRIDIUM DIFFICILE INFECTION: A SYSTEMATIC REVIEW AND META-ANALYSIS</u>
02 May 2026	<u>OUTCOMES AND SAFETY OF ORAL ANTICOAGULATION VERSUS LOVENOX FOR VENOUS THROMBOEMBOLISM IN TOTAL COLECTOMY PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A REAL-WORLD RETROSPECTIVE STUDY</u>
02 May 2026	<u>SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) AS MAINTENANCE THERAPY FOR CROHN'S DISEASE IN JAPAN: SAFETY AND EFFICACY OVER 44 WEEKS</u>
02 May 2026	<u>PREDICTING RELAPSE AND SUSTAINED REMISSION AFTER THERAPEUTIC DE-ESCALATION IN INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW OF RANDOMIZED TRIALS</u>
02 May 2026	<u>EFFICACY OF APP-DELIVERED GUT-DIRECTED HYPNOTHERAPY IN IRRITABLE BOWEL SYNDROME (IBS) PATIENTS WITH CO-MORBID INFLAMMATORY BOWEL DISEASE (IBD)</u>

Notable Presentations Information At DDW 2026

Hepatology & Liver Disease (1/4)



Date	Title
02 May 2026	<u>THE SAFETY AND CLINICAL OUTCOMES OF ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY IN PATIENTS WITH COMPENSATED AND DECOMPENSATED CIRRHOSIS: A RETROSPECTIVE MATCHED COHORT STUDY</u>
02 May 2026	<u>OUTCOMES OF ANTICOAGULATION IN PORTAL VEIN THROMBOSIS AFTER ACUTE PANCREATITIS IN A NATIONAL MULTICENTER STUDY: A CALL FOR RANDOMIZED CONTROLLED TRIALS</u>
02 May 2026	<u>THE EFFICACY AND SAFETY OF CLIP-ASSISTED ENDOSCOPIC CYANOACRYLATE INJECTION FOR GASTRIC VARICES: A SYSTEMATIC REVIEW AND META-ANALYSIS</u>
02 May 2026	<u>EFFICACY AND SAFETY OF CLIPPING PRIOR TO CYANOACRYLATE EMBOLIZATION IN GASTRIC VARICES: A SINGLE-ARM SYSTEMATIC REVIEW AND META-ANALYSIS</u>
02 May 2026	<u>MISSED OPPORTUNITIES FOR UNIVERSAL HEPATITIS C SCREENING IN A PREDOMINANTLY HISPANIC SAFETY-NET POPULATION: LANGUAGE PREFERENCE, INSURANCE STATUS, AND VISIT FREQUENCY AS INDEPENDENT DETERMINANTS OF SCREENING COMPLETION.</u>
02 May 2026	<u>DISPARITIES IN HEPATOCELLULAR CARCINOMA SURVEILLANCE AMONG A MULTI-CENTER COHORT OF PATIENTS WITH CIRRHOSIS ACROSS FIVE SAFETY-NET HEALTH SYSTEMS</u>
02 May 2026	<u>IMPLEMENTATION OF MASLD FIBROSIS SCREENING PROGRAM IN PRIMARY CARE CLINIC AT A LARGE URBAN SAFETY-NET HOSPITAL</u>
02 May 2026	<u>PROGNOSTIC SIGNIFICANCE OF A SECOND DECOMPENSATION EVENT IN PATIENTS WITH CIRRHOSIS: RESULTS FROM THE INDIANA CIRRHOSIS COHORT</u>



Notable Presentations Information At DDW 2026

Hepatology & Liver Disease (2/4)



Date	Title
02 May 2026	<u>PARABACTEROIDES DISTASONIS SUPPRESSES METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE-RELATED HEPATOCELLULAR CARCINOMA AND POTENTIATES ANTI-PD-1 EFFICACY</u>
02 May 2026	<u>COMPARISON OF GLP 1 RECEPTOR ANTAGONIST VS. SGLT2 INHIBITORS ON CLINICAL OUTCOMES IN PATIENTS WITH CIRRHOSIS: A PROPENSITY MATCHED ANALYSIS OF 10,816 PATIENTS</u>
02 May 2026	<u>COMPARISON OF FINERENONE VERSUS SPIRONOLACTONE IN PATIENTS WITH LIVER CIRRHOSIS: A PROPENSITY-MATCHED COHORT STUDY</u>
02 May 2026	<u>REAL-WORLD MULTI-CENTER COMPARISON OF DEMENTIA OUTCOMES AFTER BARIATRIC SURGERY AND GLP-1 THERAPY IN MASLD</u>
02 May 2026	<u>INTERIM ANALYSIS OF A RANDOMIZED CONTROLLED TRIAL EVALUATING ELOBIXIBAT VS VITAMIN E FOR METABOLIC ASSOCIATED STEATOTIC LIVER DISEASE (MASLD): EFFECTS ON STEATOSIS, LIVER STIFFNESS, AND METABOLIC PARAMETERS</u>
02 May 2026	<u>SAFETY OF RESMETIROM IN MASLD: A PROPENSITY SCORE-MATCHED REAL-WORLD COHORT ANALYSIS</u>
02 May 2026	<u>BILIARY SAFETY SIGNALS WITH RESMETIROM IN MASH: REAL-WORLD COMPARISON AGAINST GLP-1 RECEPTOR AGONISTS</u>
02 May 2026	<u>TRIPLE AND DUAL INCRETIN CO-AGONISTS DEMONSTRATE SUPERIOR HISTOLOGIC AND RADIOGRAPHIC EFFICACY COMPARED TO GLP-1 MONO-AGONISTS IN MASLD: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS</u>

Notable Presentations Information At DDW 2026

Hepatology & Liver Disease (3/4)



Date	Title
02 May 2026	<u>NOVEL REAL-WORLD HEAD-TO-HEAD COMPARISON OF SEMAGLUTIDE VS RESMETIROM IN MASLD: A PROPENSITY-MATCHED COHORT STUDY</u>
02 May 2026	<u>COMPARATIVE EFFICACY OF GLP-1 AGONISTS AND LIFESTYLE INTERVENTIONS ON METABOLIC DYSFUNCTIONAL-ASSOCIATED STEATOHEPATITIS: EVIDENCE FROM RANDOMIZED CONTROLLED TRIALS</u>
02 May 2026	<u>COMPARATIVE EFFICACY OF TIRZEPATIDE VS SEMAGLUTIDE FOR REDUCTION OF HEPATIC STEATOSIS IN NAFLD: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS</u>
02 May 2026	<u>SAFETY AND EFFICACY OF KETOGENIC DIET VERSUS STANDARD DIETARY RECOMMENDATION IN OBESE PATIENTS WITH COMPENSATED CIRRHOSIS FROM METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS</u>
02 May 2026	<u>EFFICACY AND SAFETY OF A MIXED HERBAL SUPPLEMENT IN NON-ALCOHOLIC FATTY LIVER DISEASE</u>
02 May 2026	<u>EFFICACY OF HERBAL PRODUCTS AND DERIVATIVES FOR IMPROVING LIVER ENZYMES AND INFLAMMATION IN MASLD: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS WITH CINEMA ASSESSMENT</u>
02 May 2026	<u>EFFICACY OF HERBAL PRODUCTS AND DERIVATIVES ON METABOLIC PARAMETERS IN MASLD PATIENTS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS WITH CINEMA ASSESSMENT</u>
02 May 2026	<u>SAFETY OF BARIATRIC SURGERY IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH): A MULTI-INSTITUTIONAL PROPENSITY-MATCHED ANALYSIS</u>

Notable Presentations Information At DDW 2026

Hepatology & Liver Disease (4/4)



Date	Title
02 May 2026	<u>EFFICACY AND SAFETY OF ILEAL BILE ACID TRANSPORT (IBAT) INHIBITORS IN PEDIATRIC CHOLESTATIC LIVER DISEASES: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS</u>
02 May 2026	<u>DIAGNOSTIC PERFORMANCE OF 19G ASPIRATION NEEDLE VERSUS 19G CORE BIOPSY NEEDLE FOR EUS GUIDED LIVER BIOPSY: A DOUBLE BLINDED PARALLEL GROUP RANDOMIZED CONTROLLED TRIAL</u>
02 May 2026	<u>EFFICACY AND SAFETY OF SI-RNA WITH NUCLEOS(T)IDE ANALOGUES IN CHRONIC HEPATITIS B: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED TRIALS</u>
02 May 2026	<u>EFFECTS OF EMPAGLIFLOZIN ON PREVENTING FIBROSIS AND CIRRHOSIS PROGRESSION IN NUCLEOS(T)IDE ANALOGUE-TREATED CHRONIC HEPATITIS B PATIENTS WITH F2-F4 FIBROSIS: A RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL</u>
03 May 2026	<u>BEYOND DRAINAGE: COMPARING ENDOSCOPIC TRANSPAPILLARY GALLBLADDER STENTING VS PERCUTANEOUS GALLBLADDER CHOLECYSTOSTOMY IN CIRRHOSIS</u>
03 May 2026	<u>A PROSPECTIVE OPEN-LABEL CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MAGNETIC COMPRESSION ANASTOMOSIS IN PATIENTS WITH BILIARY STRICTURE OR BILE DUCT DISCONNECTION FOLLOWING CHOLECYSTECTOMY AND LIVING DONOR LIVER TRANSPLANT</u>



Notable Presentations Information At DDW 2026

Pancreatic & Biliary Diseases (1/4)



Date	Title
02 May 2026	<u>COMPARISON OF SAFETY BETWEEN POWER-CONTROLLED AND TEMPERATURE-CONTROLLED INTRADUCTAL RADIOFREQUENCY ABLATION IN MALIGNANT DISTAL BILIARY OBSTRUCTION: PRELIMINARY RESULTS FROM A MULTICENTER RANDOMIZED CONTROLLED TRIAL</u>
02 May 2026	<u>IS NIL PER OS NECESSARY BEFORE ERCP? COMPARATIVE SAFETY OF MODIFIED FASTING PROTOCOLS VS TRADITIONAL FASTING: A SYSTEMATIC REVIEW AND META-ANALYSIS</u>
02 May 2026	<u>COMPARING DIFFERENT FAMILIAL PANCREATIC CANCER SYNDROME CRITERIA FOR RISK OF MALIGNANCY: FINDINGS FROM A LARGE PROSPECTIVE PANCREATIC CANCER SCREENING COHORT STUDY.</u>
02 May 2026	<u>EUS-GUIDED RADIOFREQUENCY ABLATION FOR PANCREATIC AND EXTRA-PANCREATIC LESIONS: PROSPECTIVE SINGLE-CENTER SAFETY AND EFFICACY OUTCOMES</u>
02 May 2026	<u>UPDATED RESULTS OF FEASIBILITY, SAFETY, AND TUMOR CONTROL IN TWO FIRST-IN-HUMAN TRIALS OF A NOVEL ALPHA-EMITTING RADIONUCLIDE FOR PANCREATIC ADENOCARCINOMA</u>
02 May 2026	<u>HIGH INCIDENCE OF COGNITIVE DEFICIT IN PATIENTS PRESENTING WITH ACUTE PANCREATITIS - AN UNRECOGNIZED MANIFESTATION: RESULTS OF A MULTICENTER PROSPECTIVE TRIAL</u>
02 May 2026	<u>A SINGLE EPISODE OF ACUTE PANCREATITIS CAN DOUBLE RISK OF DIABETES MELLITUS: RESULTS FROM A PROSPECTIVE STUDY OF 500,000 UK BIOBANK PARTICIPANTS WITH DETAILED PHENOTYPING AND LONGITUDINAL HEALTH DATA</u>
02 May 2026	<u>DIAGNOSTIC EFFICACY OF IMAGING VERSUS NON-IMAGING METHODS IN ADULT GALLSTONE-RELATED ACUTE PANCREATITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS</u>

Notable Presentations Information At DDW 2026

Pancreatic & Biliary Diseases (2/4)



Date	Title
02 May 2026	<u>RECURRENT STONE FORMATION RESULTING IN PANCREATITIS TREATED WITH BILIARY STENT AFTER TYPE 1 CHOLEDOCHAL CYST RESECTION</u>
02 May 2026	<u>CERES-BILAT PRELIMINARY RESULTS: A RANDOMIZED TRIAL COMPARING CERES (ERCP + EUS-HGS) VERSUS BILATERAL ERCP IN UNRESECTABLE MALIGNANT HILAR BILIARY OBSTRUCTION</u>
02 May 2026	<u>HEAD-TO-HEAD COMPARISON OF IMMEDIATE NECROSECTOMY VS. STEP-UP APPROACH FOLLOWING ENDOSCOPIC ULTRASOUND-GUIDED DRAINAGE OF NECROTIZING PANCREATITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS</u>
02 May 2026	<u>COMPARATIVE SAFETY OF ERCP IN CIRRHOTIC VS NON-CIRRHOTIC PATIENTS: A LARGE PROPENSITY-MATCHED STUDY</u>
02 May 2026	<u>REMIMAZOLAM VERSUS PROPOFOL FOR SEDATION IN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED TRIALS</u>
02 May 2026	<u>SAFETY AND EFFICACY OF GASTRO LARYNGEAL MASK AIRWAY FOR ERCP: A PROPORTION META-ANALYSIS</u>
02 May 2026	<u>FEASIBILITY AND SAFETY OF AMBULATORY ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY: A RETROSPECTIVE ANALYSIS OF SEVEN YEARS OF EXPERIENCE</u>
02 May 2026	<u>THE SAFETY OF HIGH-LEVEL DISINFECTION AND STERILIZATION FOR REPROCESSING THE SINGLE-OPERATOR CHOLANGIOSCOPY IN BILIARY TRACT DISEASES - PRELIMINARY ANALYSIS</u>



Notable Presentations Information At DDW 2026

Pancreatic & Biliary Diseases (3/4)



Date	Title
02 May 2026	<u>CLINICAL EFFICACY ANALYSIS OF EMERGENCY PANCREATIC DUCT STENT DRAINAGE FOR PATIENTS WITH ACUTE PANCREATITIS COMPLICATED BY CHOLANGITIS: A MULTICENTER RETROSPECTIVE COHORT STUDY</u>
02 May 2026	<u>HEAD-TO-HEAD COMPARISON BETWEEN RECTAL DICLOFENAC VERSUS INDOMETHACIN FOR PREVENTION OF POST-ERCP PANCREATITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS</u>
02 May 2026	<u>PANCREATIC DUCT STENTING TO PREVENT POST-ERCP PANCREATITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS</u>
02 May 2026	<u>EFFICACY AND SAFETY OF FULLY COVERED SELF-EXPANDABLE METAL STENTS WITH AND WITHOUT ANCHORING FOR BILIARY OBSTRUCTIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS.</u>
02 May 2026	<u>SAFETY OUTCOMES IN PREGNANT VERSUS NONPREGNANT WOMEN UNDERGOING ERCP: EVIDENCE FROM A NATIONAL DATABASE</u>
02 May 2026	<u>SAFETY PROFILE OF DISPOSABLE VERSUS REUSABLE DUODENOSCOPES DURING EUS-DIRECTED TRANSGASTRIC ERCP (EDGE): A MULTICENTER COMPARATIVE STUDY</u>
02 May 2026	<u>UNCOMPLICATED CHOLEDOCHOLITHIASIS IN ELDERLY PATIENTS: A TARGET TRIAL EMULATION COMPARING OBSERVATION AND ERCP (CHOICE)</u>
02 May 2026	<u>EARLY EFFICACY AND SAFETY DATA OF A NEW FULLY COVERED SELF-EXPANDING METAL STENT WITH ANTI-MIGRATORY FEATURES FOR THE MANAGEMENT OF DISTAL MALIGNANT BILIARY OBSTRUCTION: PROSPECTIVE ANALYSIS AND A PROPENSITY SCORE-MATCHED COMPARISON TO CONVENTIONAL STENTS</u>

Notable Presentations Information At DDW 2026

Pancreatic & Biliary Diseases (4/4)



Date	Title
02 May 2026	<u>EFFICACY AND UNPLANNED REINTERVENTION RATE OF A NOVEL FULLY COVERED METAL BILIARY STENT WITH ANTI-MIGRATION FEATURES – A MULTICENTER RETROSPECTIVE STUDY</u>
02 May 2026	<u>A TIGHT SPOT: SAFETY AND PERFORMANCE OF EUS-CDS IN BILE DUCTS ? 15MM</u>
02 May 2026	<u>REDUCTION IN PANCREATIC FAT FOLLOWING BARIATRIC SURGERY: RESULTS FROM A PROSPECTIVE REGISTRY</u>
02 May 2026	<u>THE TRIAGE ROLE OF TRANSABDOMINAL ULTRASONOGRAPHY (TAUS) IN THE DIAGNOSTIC MANAGEMENT OF PANCREATIC AND DISTAL BILIARY PATHOLOGIES: A COMPARATIVE EFFICACY ANALYSIS WITH ENDOSCOPIC ULTRASONOGRAPHY (EUS)</u>
02 May 2026	<u>EARLY FEEDING VERSUS DELAYED FEEDING IN MILD TO MODERATE ACUTE PANCREATITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED TRIALS</u>
02 May 2026	<u>MANAGING GALLSTONE ILEUS: A CASE COMPARISON OF ENDOSCOPIC APPROACHES AND SURGICAL ALTERNATIVES</u>

Notable Presentations Information At DDW 2026

Functional GI Disorders & Motility (1/4)



Date	Title
02 May 2026	<u>SINGING THERAPY VERSUS DIAPHRAGMATIC BREATHING FOR SUPRAGASTRIC BELCHING: A MULTICENTER RANDOMIZED CONTROLLED TRIAL</u>
02 May 2026	<u>IMPACT OF IRRITABLE BOWEL SYNDROME ON PATIENTS EXPERIENCES VARIES BY BIOLOGICAL SEX AND SEXUAL AND GENDER MINORITY STATUS: RESULTS FROM THE 2024 AGA IBS AMERICA SURVEY</u>
02 May 2026	<u>A NOVEL NONINVASIVE WEARABLE DEVICE COMBINING MECHANICAL SUPPORT AND TRANSCUTANEOUS NEUROMUSCULAR STIMULATION FOR THE TREATMENT OF FECAL INCONTINENCE - PRELIMINARY RESULTS FROM A PROSPECTIVE SINGLE-ARM CLINICAL STUDY.</u>
02 May 2026	<u>FROM PRESENTATION TO THERAPY: REAL-WORLD PATTERNS OF FECAL INCONTINENCE CARE AT A SAFETY NET HEALTH SYSTEM</u>
02 May 2026	<u>COMPARING SHORT AND LONG-TERM OUTCOMES AFTER POEM, HELLER MYOTOMY WITH FUNDOPLASTY, AND PNEUMATIC DILATION IN ACHALASIA: A REAL-WORLD MULTICENTER RETROSPECTIVE COHORT STUDY</u>
02 May 2026	<u>ELECTROACUPUNCTURE FOR FUNCTIONAL DYSPESIA: A 2x2 FACTORIAL RANDOMIZED CONTROLLED TRIAL</u>
02 May 2026	<u>EFFICACY OF PEPPERMINT OIL VERSUS PLACEBO IN THE TREATMENT OF FUNCTIONAL DYSPESIA: A MULTICENTER RANDOMIZED CONTROLLED TRIAL</u>
02 May 2026	<u>ENCAPSULATED FECAL MICROBIOTA TRANSPLANTATION FOR FUNCTIONAL DYSPESIA: A RANDOMIZED DOUBLE-BLIND TRIAL WITH GASTRIC MICROBIOTA REMODELING (FMT-FD TRIAL)</u>

Notable Presentations Information At DDW 2026

Functional GI Disorders & Motility (2/4)



Date	Title
02 May 2026	<u>EFFICACY OF UNRIPE BANANA POWDER WITH GINGER EXTRACT VERSUS UNRIPE BANANA POWDER ONLY VERSUS PLACEBO IN TREATMENT OF FUNCTIONAL DYSPEPSIA. A MULTICENTER RANDOMIZED CONTROLLED TRIAL</u>
02 May 2026	<u>PROBIOTIC MEDILAC-S COMBINED WITH ESOMEPRAZOLE IMPROVES SYMPTOMS OF FUNCTIONAL DYSPEPSIA: A PROSPECTIVE, BLOCK RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL</u>
02 May 2026	<u>THE EFFECTS OF FERMENTABLE OLIGO-,DI-, MONOSACCHARIDES AND POLYOLS(FODMAPS) MEALS ON GASTRIC MOTOR FUNCTION IN PATIENTS WITH FUNCTIONAL DYSPEPSIA: RANDOMIZED CROSS OVER TRIAL</u>
02 May 2026	<u>ASSOCIATION BETWEEN ESOPHAGOGASTRIC JUNCTION AXIAL DYNAMICS AND REFLUX BURDEN: A CROSS-SECTIONAL COMPARISON OF HILL CLASSIFICATION AND MANOMETRIC MEASUREMENTS</u>
02 May 2026	<u>A RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE II TRIAL ASSESSING THE SAFETY AND EFFICACY OF EBX-102-02, AN ORAL FULL-SPECTRUM INTESTINAL MICROBIOTA PRODUCT IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION AND DIARRHOEA; THE TRIUMPH TRIAL</u>
02 May 2026	<u>PHASE 2 TRIAL OF OPS-2071 FOR DIARRHEA PREDOMINANT IRRITABLE BOWEL SYNDROME</u>
02 May 2026	<u>EFFECT OF TJ-83 IN PATIENTS WITH IRRITABLE BOWEL SYNDROME: RANDOMIZED, PLACEBO-CONTROLLED TRIAL</u>
02 May 2026	<u>FECAL MICROBIOTA TRANSPLANTATION FOR SYMPTOM IMPROVEMENT IN PATIENTS WITH IRRITABLE BOWEL SYNDROME: SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS</u>

Notable Presentations Information At DDW 2026

Functional GI Disorders & Motility (3/4)



Date	Title
02 May 2026	<u>EFFICACY AND SAFETY OF LINACLOTIDE IN IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C): A PHASE 3 POST HOC ANALYSIS BY RACE, ETHNICITY AND AGE</u>
02 May 2026	<u>MODULATION OF GUT-BRAIN INFLAMMATION AND INTESTINAL BARRIER INTEGRITY UNDERLIES THE THERAPEUTIC EFFICACY OF CHINESE GEOHERBAL MEDICINE LU DANGSHEN IN RAT MODELS OF IBS-D</u>
02 May 2026	<u>EFFECT OF PH-MODIFYING AGENTS ON THE EFFICACY AND SAFETY OF LINACLOTIDE IN ADULTS WITH CHRONIC IDIOPATHIC CONSTIPATION (CIC) OR IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C): A POST HOC ANALYSIS</u>
02 May 2026	<u>THE OPTIMAL ROUTE OF FECAL MICROBIOTA TRANSPLANTATION FOR IRRITABLE BOWEL SYNDROME – 3 MONTHS RESULTS</u>
02 May 2026	<u>LONG-TERM CLINICAL RESPONSE AND SAFETY OF ENCAPSULATED FECAL MICROBIOTA TRANSPLANTATION (FMT) AND FMT VIA RECTAL ENEMA FOR IRRITABLE BOWEL SYNDROME (IBS): A FOUR-YEAR PROSPECTIVE COHORT STUDY</u>
02 May 2026	<u>A MULTICENTER DOUBLE-BLIND RANDOMIZED TRIAL OF AFIF FOR FUNCTIONAL DYSPEPSIA WITH NETWORK PHARMACOLOGY-BASED MECHANISTIC INSIGHTS</u>
02 May 2026	<u>NURSING INTERVENTION BASED ON BRAIN-GUT COGNITIVE-BEHAVIOR COMBINED WITH BIOFEEDBACK THERAPY CAN SIGNIFICANTLY IMPROVE SYMPTOMS AND PSYCHOLOGICAL STATE IN PATIENTS WITH FUNCTIONAL CONSTIPATION:A RANDOMIZED CONTROLLED TRIAL</u>
02 May 2026	<u>EFFECTIVENESS OF A LOW-FODMAP DIET VERSUS STANDARD DIETARY ADVICE IN IRRITABLE BOWEL SYNDROME: META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS</u>



Notable Presentations Information At DDW 2026

Functional GI Disorders & Motility (4/4)



Date	Title
02 May 2026	<u>RIFAXIMIN IMPROVES GLOBAL SYMPTOMS IN IBS-D: META-ANALYSIS OF RANDOMIZED TRIALS</u>
02 May 2026	<u>PRECISESECT MODE VERSUS FORCED COAGULATION FOR DISSECTION AND MYOTOMY IN PATIENTS UNDERGOING PERORAL ENDOSCOPIC MYOTOMY (POEM): PRELIMINARY RESULTS OF A RANDOMIZED CONTROLLED TRIAL</u>
02 May 2026	<u>EFFICACY OF CRYOABLATION IN THE PALLIATIVE TREATMENT OF DYSPHAGIA IN PATIENTS WITH ESOPHAGEAL CANCER: A RETROSPECTIVE MULTICENTER STUDY.</u>
02 May 2026	<u>EFFICAY AND SAFETY OF REDO GASTRIC PERORAL ENDOSCOPIC MYOTOMY IN REFRACTORY GASTROPARESIS: A PROSPECTIVE OUTCOMES STUDY FROM A TERTIARY CENTER</u>
02 May 2026	<u>PROBIOTICS ALTERS BRAIN STRUCTURE AND FUNCTION IN IBS: A RANDOMIZED CONTROLLED TRIAL</u>
02 May 2026	<u>LOW-FODMAP DIET VERSUS TRADITIONAL DIETARY ADVICE IN PATIENTS WITH OVERLAP OF FUNCTIONAL DYSPESIA AND IRRITABLE BOWEL SYNDROME: A PROSPECTIVE MULTI-CENTER RANDOMIZED CLINICAL TRIAL</u>

Notable Presentations Information At DDW 2026

GI Oncology & Premalignant Disease (1/4)



Date	Title
02 May 2026	<u>RELATION OF NEGATIVE FECAL IMMUNOCHEMICAL TEST RESULTS WITH RISK OF DEATH FROM COLORECTAL CANCER: COHORT STUDY</u>
02 May 2026	<u>EXTERNAL VALIDATION OF THE ESOPEC TRIAL COMPARING PERIOPERATIVE CHEMOTHERAPY WITH PREOPERATIVE CHEMORADIOTHERAPY IN ESOPHAGEAL AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA USING A POPULATION-BASED MATCHED-COHORT STUDY</u>
02 May 2026	<u>CHRONIC GASTRITIS TO GASTRIC CANCER TRANSFORMATION: A MENDELIAN RANDOMIZATION AND MULTI-OMICS ANALYSIS</u>
02 May 2026	<u>A PROSPECTIVE RANDOMIZED COMPARISON OF TWO MAIN ENDOSCOPIC METHODS FOR THE REMOVAL OF LARGE SESSILE NEOPLASMS OF THE COLON.</u>
02 May 2026	<u>GUT FUNGUS SCHIZOSACCHAROMYCES POMBE SUPPRESSES TUMORIGENESIS AND BOOSTS ANTI-PD-1 EFFICACY IN COLORECTAL CANCER</u>
02 May 2026	<u>PSEUDOBUTYRIVIBRIO XYLANIVORANS ENHANCES CHEMOTHERAPY EFFICACY IN COLORECTAL CANCER THROUGH SECA-HSC70 AXIS</u>
02 May 2026	<u>ADDING PANITUMUMAB TO FOLFOX4 OR FOLFIRI LOWERS PROGRESSION RISK BY 21% AND RAISES DISEASE CONTROL BY 38% IN KRAS WILD-TYPE METASTATIC COLORECTAL CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS</u>
02 May 2026	<u>SURVIVAL OUTCOMES IN METASTATIC COLORECTAL CANCER PATIENTS WITH BRAF MUTATIONS UNDERGOING CHEMOTHERAPY: A RECONSTRUCTED INDIVIDUAL PATIENT-DATA META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS</u>



Notable Presentations Information At DDW 2026

GI Oncology & Premalignant Disease (2/4)



Date	Title
02 May 2026	<u>AGE AS THE PRIMARY PREDICTOR OF ADVANCED COLORECTAL CANCER IN A SAFETY NET POPULATION</u>
02 May 2026	<u>HOW COLORECTAL CANCER COMES TO ATTENTION IN A PUBLIC SAFETY-NET HOSPITAL</u>
02 May 2026	<u>SRSF1 LIQUID-LIQUID PHASE SEPARATION DRIVES RAI14 ALTERNATIVE SPLICING TO PROMOTE CHEMORESISTANCE IN EARLY-ONSET GASTRIC CANCER</u>
02 May 2026	<u>TARGETING MULTIVALENT RECEPTOR TYROSINE KINASES TO ENHANCE ANTI-PD-1 IMMUNOTHERAPY EFFICACY IN GASTRIC CANCER</u>
02 May 2026	<u>EFFICACY AND SAFETY OF DUAL-IMMUNE CHECKPOINT INHIBITOR THERAPY IN MICROSATELLITE INSTABILITY HIGH COLORECTAL CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS</u>
02 May 2026	<u>COMPARISON BETWEEN ENDOSCOPIC SUBMUCOSAL DISSECTION/ENDOSCOPIC FULL THICKNESS RESECTION AND TRANS-ANAL ENDOSCOPIC MICROSURGERY IN RECTAL NEUROENDOCRINE TUMORS < 20 MM: A META-ANALYSIS AND SYSTEMATIC REVIEW</u>
02 May 2026	<u>THE EFFICACY OF ENDOSCOPIC ULTRASOUND GUIDED BIOPSIES TO SUCCESSFULLY GENERATE PATIENT DERIVED DOWNSTREAM PDAC MODELS FROM A SINGLE PROCEDURE</u>
02 May 2026	<u>EFFICACY AND SAFETY OF RADIOTHERAPY FOLLOWED BY ENDOSCOPIC SUBMUCOSAL DISSECTION FOR T1 SUPERFICIAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A CASE SERIES STUDY</u>



Notable Presentations Information At DDW 2026

GI Oncology & Premalignant Disease (3/4)



Date	Title
02 May 2026	<u>EFFICACY OF PARTIAL-INJECTION UNDERWATER EMR FOR DUODENAL EPITHELIAL TUMORS: A SINGLE-CENTER RANDOMIZED CONTROLLED TRIAL</u>
02 May 2026	<u>COMPARATIVE EFFICACY AND SAFETY OF GEL-IMMERSION ENDOSCOPIC MUCOSAL RESECTION (GI-EMR) VERSUS UNDERWATER EMR (UEMR) FOR SUPERFICIAL NON-AMPULLARY DUODENAL EPITHELIAL TUMORS: A SYSTEMATIC REVIEW AND META-ANALYSIS</u>
02 May 2026	<u>COMPARISON OF ENDOSCOPIC RESECTION AND SURGERY FOR EARLY GASTRIC CANCER WITH UNDIFFERENTIATED HISTOLOGIC TYPE (ERASE-GC TRIAL): A REPORT OF BASELINE RESULTS</u>
03 May 2026	<u>HIGH SENSITIVITY OF NEXT-GENERATION SEQUENCING ON BILE-DERIVED CELL-FREE DNA FOR MUTATION-BASED DIAGNOSIS OF PERIHILAR CHOLANGIOCARCINOMA: FIRST RESULTS FROM THE PROSPECTIVE BAMBI STUDY</u>
03 May 2026	<u>TECHNICAL SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED STUDIES DEDICATED TO MALIGNANT DISTAL BILIARY OBSTRUCTION</u>
03 May 2026	<u>EFFICACY AND SAFETY OF ENDOSCOPIC ULTRASOUND-GUIDED CHOLEDOCHODUODENOSTOMY (EUS-CDS) COMPARED WITH ENDOSCOPIC ULTRASOUND-GUIDED GALLBLADDER DRAINAGE (EUS-GBD) FOR PALLIATION OF MALIGNANT DISTAL BILIARY OBSTRUCTION: A SYSTEMATIC REVIEW AND META-ANALYSIS</u>
03 May 2026	<u>ULTRA-PROCESSED FOOD INTAKE IN PATIENTS WITH BARRETT'S ESOPHAGUS AND ASSOCIATED NEOPLASIA: RESULTS OF A MULTICENTER CROSS-SECTIONAL STUDY</u>
03 May 2026	<u>LOW RECURRENCE RATES AFTER ENDOSCOPIC ERADICATION THERAPY WITH RFA OF BARRETT'S NEOPLASIA: LONG-TERM FOLLOW-UP RESULTS FROM THE DUTCH BARRETT'S REGISTRY</u>



Notable Presentations Information At DDW 2026

GI Oncology & Premalignant Disease (4/4)



Date	Title
03 May 2026	<u>PREDICTORS OF NEOPLASTIC RECURRENCE AFTER SUCCESSFUL ENDOSCOPIC ERADICATION THERAPY OF BARRETT'S NEOPLASIA BASED ON LONG-TERM FOLLOW-UP RESULTS FROM THE DUTCH BARRETT'S REGISTRY.</u>
03 May 2026	<u>ASSOCIATION OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST USE WITH RISK OF BILIARY DISEASES AND BILIARY CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS</u>
03 May 2026	<u>A MULTIMODAL NOMOGRAM FOR RISK STRATIFICATION IN INDETERMINATE BILIARY STRICTURES: ENHANCING DIAGNOSIS BEYOND INITIAL NON-MALIGNANT BIOPSY RESULTS</u>
03 May 2026	<u>MORTALITY FROM PANCREATIC CANCER RESULTS FROM SEPSIS, THROMBOSIS AND ORGAN FAILURE WITH TERMINAL HYPOALBUMINEMIA AND HYPOCALCEMIA.</u>
03 May 2026	<u>PROTOCOL-DRIVEN EUS-GUIDED SAMPLING RESULTS IN HIGH YIELD OF NEXT GENERATION SEQUENCING IN PANCREATIC DUCTAL ADENOCARCINOMA</u>
03 May 2026	<u>THREE-WAY COMPARISON OF CONCURRENT EUS-GUIDED RFA, RADIOTHERAPY, AND CHEMOTHERAPY IN UNRESECTABLE PANCREATIC CANCER: OUTCOMES AND TOXICITY PROFILE</u>

Notable Presentations Information At DDW 2026

Endoscopy & Advanced Therapeutic Procedures (1/4)



Date	Title
02 May 2026	<u>INDICATIONS AND RESULTS OF ENDOSCOPIC RESECTIONS</u>
02 May 2026	<u>BOTULINUM TOXIN INJECTION IN THE UES FOR RETROGRADE CRICOPHARYNGEUS DYSFUNCTION (BOTUS R-CPD): FIRST RESULTS OF A TRIPLE-BLIND RANDOMIZED CONTROLLED TRIAL</u>
02 May 2026	<u>SAFETY AND EFFICACY OF HEMOSTATIC AGENTS IN PATIENTS WITH POST-SPHINCTEROTOMY OR POST-ENDOSCOPIC PAPILLECTOMY BLEEDING: A SYSTEMATIC REVIEW AND META-ANALYSIS</u>
02 May 2026	<u>COMPUTER-AIDED ADENOMA DETECTION IN ROUTINE COLONOSCOPY: A CONCEALED MULTICENTER RANDOMIZED TRIAL</u>
02 May 2026	<u>POSITIVE AND NEGATIVE PREDICTIVE VALUE OF A NON-ENDOSCOPIC MOLECULAR BARRETT'S ESOPHAGUS DETECTION TEST IN SCREENING ELIGIBLE ADULTS: FINAL RESULTS FROM A LARGE MULTICENTER POPULATION BASED CLINICAL TRIAL</u>
02 May 2026	<u>SAFETY OF ENDOSCOPIC DRAINAGE AND NECROSECTOMY WITH RESPECT TO BLEEDING: A LARGE COHORT STUDY</u>
02 May 2026	<u>THE SAFETY, EFFICACY AND TOLERABILITY OF L-ARABINOSE FOR BOWEL PREPARATION BEFORE COLONOSCOPY</u>
02 May 2026	<u>ENDOSCOPIC SAFETY IN SEVERE THROMBOCYTOPENIA: NO BENEFIT OF PROPHYLACTIC PLATELET TRANSFUSION ABOVE</u> <u>1</u>



Notable Presentations Information At DDW 2026

Endoscopy & Advanced Therapeutic Procedures (2/4)



Date	Title
02 May 2026	<u>COMPARISON OF SUTURING VERSUS CLIPS FOR MUCOSOTOMY CLOSURE IN THIRD-SPACE PROCEDURES</u>
02 May 2026	<u>COMPARISON OF TRANEXAMIC ACID VERSUS EPINEPHRINE USE DURING COLONIC ENDOSCOPIC MUCOSAL RESECTION PROCEDURES FOR THE REDUCTION OF INTRAPROCEDURAL AND POSTPROCEDURAL COMPLICATIONS.</u>
02 May 2026	<u>SAFETY AND FEASIBILITY OF OUTPATIENT ENDOSCOPIC SUBMUCOSAL DISSECTION IN THE UNITED STATES: OUTCOMES FROM THE LARGEST SINGLE-CENTER COHORT</u>
02 May 2026	<u>ENDOSCOPIC SUBMUCOSAL DISSECTION OUTCOMES FOR VULNERABLE POPULATIONS: MULTICENTER RETROSPECTIVE EVALUATION IN SAFETY-NET HOSPITALS ACROSS THE UNITED STATES</u>
02 May 2026	<u>TOO NEUTROPENIC TO SCOPE? ANALYSIS OF EGD SAFETY IN NEUTROPENIC PATIENTS USING REAL WORLD DATA</u>
02 May 2026	<u>SAFETY PROFILE, PATIENT, AND DEVICE-RELATED ADVERSE EVENTS OF PERCUTANEOUS ENDOSCOPIC GASTROSTOMY (PEG) TUBES: A REPORT FROM MANUFACTURER AND USER FACILITY DEVICE EXPERIENCE (MAUDE) DATABASE ANALYSIS</u>
02 May 2026	<u>THIRTY-DAY SAFETY AND HEALTHCARE UTILIZATION AFTER LAMS PLACEMENT: INSIGHTS FROM THE TRINETX DATABASE</u>
02 May 2026	<u>COMPARISON OF POLYETHYLENE GLYCOL-BASED SOLUTIONS AND ORAL SULFATE TABLETS FOR BOWEL PREPARATION: IMPACTS ON COLONOSCOPY QUALITY AND GASTRIC MUCOSAL SAFETY</u>

Notable Presentations Information At DDW 2026

Endoscopy & Advanced Therapeutic Procedures (3/4)



Date	Title
02 May 2026	<u>PROPHYLACTIC HEMOCLIPS IN PREVENTION OF DELAYED POST-POLYPECTOMY BLEEDING FOR COLORECTAL POLYPS: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS WITH TRIAL SEQUENTIAL ANALYSIS</u>
02 May 2026	<u>PERFORMANCE AND SAFETY OF A NEXT GENERATION 22GA EUS-FNB NEEDLE</u>
02 May 2026	<u>SAFETY OF EUS-GUIDED FNA/FNB IN PATIENTS RECEIVING DUAL ANTIPLATELET THERAPY: INSIGHTS FROM A LARGE REAL-WORLD COHORT</u>
02 May 2026	<u>SAFETY AND EFFICACY OF ENDOSCOPIC SLEEVE GASTROPLASTY IN PATIENTS WITH A BMI ≥ 50 KG/M2: A SYSTEMATIC REVIEW</u>
02 May 2026	<u>EFFICACY AND SAFETY OF EUS-GUIDED PELVIC ABSCESS DRAINAGE USING LUMEN-APOSING METAL STENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS</u>
02 May 2026	<u>REAL-WORLD MULTICENTER STUDY COMPARING OUTCOMES OF EUS HEPATICOGASTROSTOMY BETWEEN EAST VS WEST IN 1082 PATIENTS</u>
02 May 2026	<u>SAFETY OF RESEARCH ESOPHAGEAL BIOPSIES IN PEDIATRIC ENDOSCOPY</u>
02 May 2026	<u>A COMPARISON OF THE UPRIGHT SEATED VS. LEFT LATERAL DECUBITUS POSITION DURING SEDATION-FREE TRANSNASAL ENDOSCOPY</u>

Notable Presentations Information At DDW 2026

Endoscopy & Advanced Therapeutic Procedures (4/4)



Date	Title
02 May 2026	<u>THE IMPACT OF LUMEN VISUAL INSPECTION ON THE QUALITY OF ENDOSCOPIC REPROCESSING AND MAINTENANCE COSTS OF HIGH-FREQUENCY USE: A PROSPECTIVE RANDOMIZED CONTROLLED STUDY</u>
02 May 2026	<u>TO TEST OR NOT TO TEST? (RE)INTEGRATION CULTURES IMPROVE MICROBIOLOGICAL SAFETY IN ENDOSCOPY: PRELIMINARY RESULTS OF A PROSPECTIVE STUDY</u>
02 May 2026	<u>SAFETY OF GASTROINTESTINAL LUMINAL STENTS PLACEMENT IN PATIENTS RECEIVING ANTITHROMBOTIC THERAPY: A MULTICENTER MATCHED COHORT STUDY</u>
02 May 2026	<u>EFFICACY OF DUODENOSCOPE CAP-ASSISTED HIGH-LEVEL DISINFECTION IN REDUCING MICROBIAL CONTAMINATION: A SYSTEMATIC REVIEW AND META-ANALYSIS</u>
02 May 2026	<u>COLD SNARE POLYPECTOMY VERSUS COLD SNARE POLYPECTOMY WITH SUBMUCOSAL INJECTION FOR COLORECTAL POLYPS 3-9 MM: A RANDOMIZED CONTROLLED TRIAL</u>
02 May 2026	<u>ACETIC ACID-ASSISTED ENDOSCOPIC COLD SNARE POLYPECTOMY FOR COLORECTAL SESSILE SERRATED LESION OF 5~9 MM: A MULTICENTER RANDOMIZED CONTROLLED TRIAL (THE "ACOSER" STUDY)</u>



Notable Presentations Information At DDW 2026

Upper GI, Esophageal, GERD & Gastroparesis Disorders (1/4)

Date	Title
03 May 2026	<u>A PHASE 1, OPEN-LABEL STUDY TO EVALUATE VONOPRAZAN CONCENTRATIONS IN BREAST MILK OF HEALTHY LACTATING WOMEN RECEIVING VONOPRAZAN 20 MG ONCE DAILY OR VONOPRAZAN 20 MG TWICE DAILY</u>
03 May 2026	<u>THORACIC MAGNETIC NEUROMODULATION FOR DIABETIC GASTROPARESIS: FIRST-IN-HUMAN EVIDENCE FROM A RANDOMIZED, SHAM-CONTROLLED TRIAL</u>
03 May 2026	<u>OPEN LABEL EFFICACY ANALYSIS OF TRADIPITANT IN IDIOPATHIC AND DIABETIC GASTROPARESIS</u>
03 May 2026	<u>EFFICACY AND SAFETY OF TRAZPIROBEN IN GASTROPARESIS: A SYSTEMATIC REVIEW AND META-ANALYSIS</u>
03 May 2026	<u>EFFICACY AND SAFETY OF ORAL METOCLOPRAMIDE VS NASAL METOCLOPRAMIDE IN PEOPLE WITH DIABETIC GASTROPARESIS: META-ANALYSIS OF CLINICAL TRIALS</u>
03 May 2026	<u>EFFICACY AND SAFETY OF ANTI-REFLUX MUCOSAL ABLATION (ARMA) FOR PROTON PUMP INHIBITOR-REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS</u>
03 May 2026	<u>SHORT, MEDIUM- AND LONG-TERM OUTCOMES FOR CONCOMITANT HIATAL HERNIA REPAIR WITH TRANSORAL INCISIONLESS FUNDOPLICATION: 3-YEAR RESULTS FROM A HIGH-VOLUME CENTER</u>
03 May 2026	<u>COMPARATIVE EFFECTIVENESS AND SAFETY OF TRANSORAL INCISIONLESS FUNDOPLICATION VERSUS LAPAROSCOPIC FUNDOPLICATION FOR REFRACTORY GERD: A MATCHED MULTICENTER COHORT STUDY</u>

Notable Presentations Information At DDW 2026

Upper GI, Esophageal, GERD & Gastroparesis Disorders (2/4)



Date	Title
03 May 2026	<u>SAFETY AND EFFICACY OF TRANSORAL INCISIONLESS FUNDOPLICATION (TIF2.0) FOR THE TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE: FIRST RESULTS FROM THE EUROPEAN TIF REGISTRY (EURO-TIF)</u>
03 May 2026	<u>EFFICACY AND SAFETY OF TRANSORAL INCISIONLESS FUNDOPLICATION (TIF) FOR POST-POEM GERD: A SYSTEMATIC REVIEW AND META-ANALYSIS</u>
03 May 2026	<u>SAFETY AND FEASIBILITY OF SAME-DAY DISCHARGE (SDD) AFTER TRANSORAL INCISIONLESS FUNDOPLICATION (TIF): A PROSPECTIVE SINGLE-CENTER EXPERIENCE</u>
03 May 2026	<u>COMPARING THE CLINICAL UTILITY BETWEEN 96-HOUR AND 48-HOUR BRAVO PH MONITORING</u>
03 May 2026	<u>RESPONDER ANALYSIS FOR THE EFFICACY OF TRADIPITANT IN IDIOPATHIC AND DIABETIC GASTROPARESIS</u>
03 May 2026	<u>NARONAPRIDE IN IDIOPATHIC AND DIABETIC GASTROPARESIS: RESULTS FROM A PHASE 2B RANDOMIZED CONTROL TRIAL</u>
03 May 2026	<u>EFFICACY AND RECOVERY OF REMIMAZOLAM VERSUS MIDAZOLAM FOR SEDATION DURING GASTROINTESTINAL ENDOSCOPY: A MULTICENTER RANDOMIZED CONTROLLED TRIAL IN JAPAN (RECOVER STUDY)</u>
03 May 2026	<u>HEMODYNAMIC AND RESPIRATORY SAFETY OF REMIMAZOLAM VERSUS PROPOFOL IN ERCP: META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS.</u>

Notable Presentations Information At DDW 2026

Upper GI, Esophageal, GERD & Gastroparesis Disorders (3/4)



Date	Title
04 May 2026	<u>EFFECTIVENESS AND SAFETY OF FULL-THICKNESS VERSUS CIRCULAR MUSCLE MYOTOMY IN PERORAL ENDOSCOPIC MYOTOMY: A RANDOMIZED CONTROLLED NON-INFERIORITY TRIAL</u>
05 May 2026	<u>DUPILUMAB IMPROVES ESOPHAGEAL DISTENSIBILITY IN ADULTS WITH EOSINOPHILIC ESOPHAGITIS: 24-WEEK RESULTS FROM THE RANDOMIZED, PLACEBO-CONTROLLED REMODELING WITH DUPILUMAB IN EOSINOPHILIC ESOPHAGITIS LONG-TERM (REMODEL) TRIAL</u>
05 May 2026	<u>TEGOPRAZAN PROVIDES SUPERIOR 24-WEEK MAINTENANCE OF HEALING AND CONTROL OF HEARTBURN SYMPTOMS IN PATIENTS WITH EROSIVE ESOPHAGITIS: RESULTS FROM THE PHASE 3 TRIUMPH STUDY</u>
05 May 2026	<u>PCABS ARE ASSOCIATED WITH LOW RATES OF SHORT-TERM ADVERSE EVENTS: A GLOBAL COHORT STUDY COMPARING PCABS VERSUS PPIS</u>
05 May 2026	<u>BEYOND THE TRIAL: REAL-WORLD EVIDENCE OF FDA-APPROVED BUDESONIDE ORAL SUSPENSION CONFIRMS CLINICAL EFFICACY ACROSS HISTOLOGIC, ENDOSCOPIC, AND SYMPTOMATIC OUTCOMES</u>
05 May 2026	<u>HEAD-TO-HEAD COMPARISON OF SYSTEMIC ORAL STEROIDS, SWALLOWED TOPICAL STEROIDS, AND PROTON PUMP INHIBITORS IN EOSINOPHILIC ESOPHAGITIS: A PROPENSITY-MATCHED REAL-WORLD STUDY</u>
05 May 2026	<u>DETERMINATION OF DOSE AND INJECTION PATTERN OF EP-104GI THROUGH DOSE ESCALATION IN RESOLVE: A PHASE 1B/2, MULTICENTER TRIAL TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY IN ADULTS WITH EOE</u>
05 May 2026	<u>CORRELATING THE EOSINOPHILIC ESOPHAGITIS HISTOLOGY SCORING SYSTEM (EOEHSS) WITH PEAK ESOPHAGEAL EOSINOPHIL COUNTS: POOLED RESULTS FROM EOE KIDS AND LIBERTY EOE TREET</u>



Notable Presentations Information At DDW 2026

Upper GI, Esophageal, GERD & Gastroparesis Disorders (4/4)



Date	Title
05 May 2026	<u>SINGLE ADMINISTRATION OF EP-104GI IN RESOLVE, A PHASE 1B/2 TRIAL IN EOSINOPHILIC ESOPHAGITIS, IMPROVES ENDOSCOPIC FEATURES OF INFLAMMATION AND FIBROSIS OVER 36 WEEKS</u>
05 May 2026	<u>LONG-TERM EFFICACY AND SAFETY OF PERORAL ENDOSCOPIC MYOTOMY (POEM) VERSUS PNEUMATIC DILATION IN ACHALASIA PATIENTS WITH PRIOR LAPAROSCOPIC HELLER MYOTOMY: 5-YEAR FOLLOW-UP RESULTS FROM A MULTICENTER RANDOMIZED CONTROLLED TRIAL</u>
05 May 2026	<u>PERORAL ENDOSCOPIC PLICATION OF THE ESOPHAGUS (POPE) FOR ADVANCED ESOPHAGEAL MOTILITY DISORDERS: A MULTICENTER STUDY OF SAFETY AND EFFICACY</u>
05 May 2026	<u>ADVENTITIAL PLANE INJECTION WITH TARGETED INTERMUSCULAR INJECTION AS A NOVEL APPROACH TO ENHANCE SAFETY AND PRECISION DURING PERORAL ENDOSCOPIC MYOTOMY: A PROSPECTIVE CONTROLLED STUDY</u>
05 May 2026	<u>PROSPECTIVE RANDOMIZED CONTROLLED TRIAL COMPARING CLINICAL OUTCOMES BETWEEN UNDERWATER VERSUS CARBON DIOXIDE INSUFFLATION DURING PERORAL ENDOSCOPIC MYOTOMY (U-POEM TRIAL)</u>

Notable Presentations Information At DDW 2026

Microbiome, Immunology, Celiac Disease & Translational Science (1/4)



Date	Title
02 May 2026	<u>SAFETY OF GUSELKUMAB IN PATIENTS AGED ≥60 YEARS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES: A POOLED ANALYSIS OF REGISTRATIONAL TRIALS IN UC, CD, PSA AND PSO</u>
02 May 2026	<u>EFFICACY AND SAFETY OF KEVERPRAZAN-AMOXICILLIN DUAL THERAPY FOR HELICOBACTER PYLORI FIRST-LINE TREATMENT: A MULTICENTER, OPEN-LABEL, RANDOMIZED CONTROLLED TRIAL</u>
02 May 2026	<u>PSYCHOMETRIC VALIDATION OF THE CELIAC DISEASE SYMPTOM DIARY V2.1 USING DATA FROM A PHASE 2 STUDY IN PATIENTS WITH MODERATE TO SEVERE CELIAC DISEASE</u>
02 May 2026	<u>MEANINGFUL SYMPTOM CHANGE IN CELIAC DISEASE: QUALITATIVE FINDINGS FROM AN EXIT INTERVIEW STUDY FOLLOWING A PHASE 2 CLINICAL TRIAL</u>
02 May 2026	<u>ANTIGEN-SPECIFIC PEPTIDE IMMUNOTHERAPY FOR CELIAC DISEASE: A PRISMA-GUIDED SYSTEMATIC REVIEW OF EARLY-PHASE TRIALS TARGETING DURABLE IMMUNE TOLERANCE</u>
02 May 2026	<u>ESOPHAGEAL MAST CELLS AND T-CELLS PERSIST IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS AFTER MEPOLIZUMAB TREATMENT: SUBANALYSIS FROM A RANDOMIZED TRIAL</u>
02 May 2026	<u>METABOLIC STRESS AND GOBLET CELL LOSS IN RESPONSE TO LOSS OF METABOLIC REGULATOR, CREATINE TRANSPORTER, RESULTS IN INCREASED RISK OF INFECTIOUS COLITIS</u>
03 May 2026	<u>BUDESONIDE ORODISPERSIBLE TABLET IS SUPERIOR TO PANTOPRAZOLE IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS PRESENTING INITIALLY WITH FOOD BOLUS IMPACTION: A RANDOMISED CONTROLLED TRIAL</u>

Notable Presentations Information At DDW 2026

Microbiome, Immunology, Celiac Disease & Translational Science (2/4)



Date	Title
03 May 2026	<u>SINGLE ADMINISTRATION OF ESCALATING DOSES OF EP-104GI LEADS TO PERSISTENT IMPROVEMENTS IN HISTOLOGICAL FEATURES OF EOSINOPHILIC ESOPHAGITIS OVER 36 WEEKS IN RESOLVE, A PHASE 1B/2 DOSE ESCALATION AND OPTIMIZATION TRIAL</u>
03 May 2026	<u>VONOPRAZAN-TETRACYCLINE DUAL THERAPY AS A SIMPLIFIED RESCUE REGIMEN FOR HELICOBACTER PYLORI: A RANDOMIZED NON-INFERIORITY TRIAL</u>
03 May 2026	<u>SELF-ASSEMBLING PEPTIDE HYDROGEL TO PREVENT DELAYED BLEEDING AFTER COLORECTAL EMR, ESD, AND COLD SNARE POLYPECTOMY: A TECHNIQUE-SPECIFIC SYSTEMATIC REVIEW INCLUDING A MULTICENTER RANDOMIZED TRIAL</u>
03 May 2026	<u>GASTROINTESTINAL SYMPTOM BURDEN IN AUTOIMMUNE GASTRITIS: RESULTS FROM A STRUCTURED PATIENT QUESTIONNAIRE STUDY</u>
03 May 2026	<u>CLINICAL EFFICACY OF PROBIOTICS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE – A DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL</u>
03 May 2026	<u>DUODENAL MICROBIOTA IN SMALL INTESTINAL BACTERIAL OVERGROWTH: A COMPARISON BETWEEN CULTURE OF ASPIRATES AND METAGENOMIC ANALYSIS OF MUCOSA-ASSOCIATED MICROBIOTA</u>
03 May 2026	<u>EXPANDING THE ROLE OF IL-23 INHIBITORS: EFFICACY AND SAFETY IN IMMUNE-RELATED ADVERSE EVENTS</u>
03 May 2026	<u>EFFICACY OF ICOTROKINRA, THE FIRST TARGETED ORAL PEPTIDE THAT SELECTIVELY BLOCKS THE INTERLEUKIN-23 RECEPTOR, IN ULCERATIVE COLITIS PATIENTS WITH OR WITHOUT PRIOR INTOLERANCE OR INADEQUATE RESPONSE TO ADVANCED THERAPIES: RESULTS FROM THE ANTHEM-UC STUDY</u>

Notable Presentations Information At DDW 2026

Microbiome, Immunology, Celiac Disease & Translational Science (3/4)



Date	Title
03 May 2026	<u>GASTROINTESTINAL AND HEPATOBIILIARY SAFETY OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN DIABETIC PATIENTS WITH BARIATRIC SURGERIES</u>
04 May 2026	<u>REAL-WORLD COMPARISON OF IMMUNE-MEDIATED HEPATITIS IN PATIENTS TREATED WITH IPILIMUMAB VERSUS PROGRAMMED CELL DEATH PATHWAY INHIBITOR MONOTHERAPIES</u>
04 May 2026	<u>INTERMITTENT OR CONTINUOUS THERAPY WITH BUDESONIDE ORODISPERSIBLE TABLET FOR MAINTENANCE OF REMISSION IN EOSINOPHILIC ESOPHAGITIS: RESULTS FROM A RANDOMIZED, CONTROLLED PHASE 3 TRIAL</u>
04 May 2026	<u>FAECAL MICROBIOTA TRANSPLANTATION FOR ACTIVE CROHN'S DISEASE: THE MIRO (MICROBIAL RESTORATION) RANDOMISED PLACEBO-CONTROLLED TRIAL.</u>
04 May 2026	<u>RANDOMIZED CLINICAL TRIAL OF INFlixIMAB VERSUS VEDOLIZUMAB FOR IMMUNE CHECKPOINT INHIBITOR RELATED COLITIS</u>
04 May 2026	<u>ASSOCIATION OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST USE WITH RISK OF CHOLELITHIASIS AND CHOLECYSTITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS</u>
04 May 2026	<u>EFFICACY AND SAFETY OF CELIAC PLEXUS BLOCK IN CHRONIC PANCREATITIS: A MULTICENTER COHORT STUDY</u>
04 May 2026	<u>YOGHURT SUPPLEMENTATION MODULATES GUT MICROBIOME NETWORK AND LOWERS SYSTEMIC INFLAMMATION IN CRITICAL CARE - A PILOT RANDOMIZED CONTROLLED TRIAL</u>

Notable Presentations Information At DDW 2026

Microbiome, Immunology, Celiac Disease & Translational Science (4/4)



Date	Title
04 May 2026	<u>TARGETED MICROBIOTA INTERVENTIONS FOR MODULATING THE GUT-CARDIAC AXIS IN HEART FAILURE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED TRIALS</u>
04 May 2026	<u>ENGRAFTMENT AND MICROBIOME AND METABOLOME RESTORATION IN CDI-SCOPE, A PHASE 3B TRIAL OF FECAL MICROBIOTA, LIVE-JSLM ADMINISTERED BY COLONOSCOPY FOR PREVENTION OF RECURRENT CLOSTRIDIODES DIFFICILE INFECTION</u>
04 May 2026	<u>FEASIBILITY AND SYMPTOM-IMPROVEMENT SIGNALS OF ORAL ENCAPSULATED VERSUS COLONOSCOPY FECAL MICROBIOTA TRANSPLANTATION FOR IBS: A DOUBLE-BLIND RANDOMIZED PILOT TRIAL (CAP-COLONO STUDY)</u>
04 May 2026	<u>DIETARY MODULATION OF THE GUT-BRAIN IMMUNE AXIS IN MULTIPLE SCLEROSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED TRIALS</u>
04 May 2026	<u>RISK OF NEW-ONSET CONSTIPATION ASSOCIATED WITH GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1) USE: RESULTS FROM A NATIONWIDE COHORT STUDY</u>
04 May 2026	<u>RANDOMIZED CONTROLLED TRIAL OF MULTI-STRAIN PROBIOTICS IN FUNCTIONAL ABDOMINAL BLOATING AND DISTENSION: CLINICAL, INTESTINAL PERMEABILITY, AND MICROBIOTA OUTCOMES</u>

Notable Presentations Information At DDW 2026

Obesity, Nutrition & Surgical Innovation (1/4)



Date	Title
02 May 2026	<u>PERSONALIZED PHENOTYPE-BASED INTERVENTIONS MITIGATE HORMONAL ADAPTATIONS AND ENHANCE SATIETY IN OBESITY MANAGEMENT: EVIDENCE FROM A NON-RANDOMIZED CLINICAL TRIAL</u>
02 May 2026	<u>INCREASING LEVELS OF TOOLKIT IMPLEMENTATION IN A NATIONWIDE QUALITY IMPROVEMENT INITIATIVE ARE ASSOCIATED WITH DECREASING LEVELS OF URGENT CARE UTILIZATION: RESULTS FROM THE IBD QORUS URGENT CARE BREAKTHROUGH SERIES</u>
03 May 2026	<u>BUT IS IT REALLY SILENT? ANALYSIS OF SOUNDS MADE DURING FEEDING MAY PROVIDE INSIGHT INTO SWALLOW SAFETY IN CHILDREN WITH OROPHARYNGEAL DYSPHAGIA</u>
03 May 2026	<u>TISSUE WELDING USING RADIOFREQUENCY ENERGY FOR BOWEL ANASTOMOSIS: RESULTS OF AN IN-VIVO PORCINE STUDY</u>
03 May 2026	<u>OPEN-LABEL RANDOMIZED CONTROLLED STUDY OF SALT-RESTRICTED VERSUS SALT-UNRESTRICTED DIET IN CIRRHOSIS PATIENTS WITH MODERATE TO SEVERE HYPONATREMIA</u>
03 May 2026	<u>PROGNOSTIC COMPARISON OF ENDOSCOPIC SUBMUCOSAL DISSECTION VERSUS SURGERY FOR UNDIFFERENTIATED EARLY GASTRIC CANCER: A TAIWAN MULTICENTER STUDY</u>
03 May 2026	<u>EUS-GASTROENTEROOSTOMY VS SURGICAL GASTROJEJUNOSTOMY FOR GASTRIC OUTLET OBSTRUCTION: AN UPDATED META-ANALYSIS INCLUDING RANDOMIZED CONTROLLED TRIALS</u>
03 May 2026	<u>NETWORK META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS COMPARING ENDOSCOPIC ULTRASOUND-GUIDED GASTROJEJUNOSTOMY, ENTERIC STENTING, AND SURGICAL GASTROJEJUNOSTOMY IN MALIGNANT GASTRIC OUTLET OBSTRUCTION</u>



Notable Presentations Information At DDW 2026

Obesity, Nutrition & Surgical Innovation (2/4)



Date	Title
03 May 2026	<u>COMPARATIVE EFFECTIVENESS AND SAFETY OF EUS-GUIDED GASTROENTEROSTOMY VERSUS SURGICAL GASTROENTEROSTOMY FOR TREATMENT OF MALIGNANT GASTRIC OUTLET OBSTRUCTION: A COMPREHENSIVE SYSTEMATIC REVIEW AND META-ANALYSIS</u>
03 May 2026	<u>EFFICACY OF ENDOSCOPIC ULTRASOUND GUIDED GASTROENTEROSTOMY VERSUS SURGICAL GASTROENTEROSTOMY IN MALIGNANT GASTRIC OUTLET OBSTRUCTION: A SYSTEMATIC REVIEW AND META-ANALYSIS</u>
03 May 2026	<u>ABNORMAL VAGAL NERVE RESPONSE ON MODIFIED SHAM FEEDING TEST IS ASSOCIATED WITH HIGHER LATE-PHASE GASTRIC AMPLITUDE AND A PROLONGED MEAL RESPONSE DURING BODY SURFACE GASTRIC MAPPING</u>
03 May 2026	<u>DOMPERIDONE EXPANDED ACCESS PROGRAM: AN INTERIM REVIEW OF SAFETY AND EFFICACY</u>
03 May 2026	<u>COMPARATIVE OUTCOMES AND SAFETY OF ERCP AT SAFETY-NET VS ACADEMIC CENTERS: A PROPENSITY-MATCHED ANALYSIS</u>
03 May 2026	<u>DISPARITIES IN ENDOSCOPIC THERAPY FOR EARLY ESOPHAGEAL AND GASTRIC CANCERS: A SURVEILLANCE EPIDEMIOLOGY AND END RESULTS (SEER) ANALYSIS FROM 2013 TO 2022</u>
03 May 2026	<u>GLOBAL PERSPECTIVES ON SUSTAINABLE INFLAMMATORY BOWEL DISEASE CARE: RESULTS FROM AN INTERNATIONAL SURVEY</u>
03 May 2026	<u>FRUCTANS BOOST COLONIC FERMENTATION BUT DO NOT AGGRAVATE SYMPTOMS IN NON-CONSTIPATED IBS PATIENTS ON A LOW FODMAP DIET - A RANDOMIZED CONTROLLED TRIAL</u>

Notable Presentations Information At DDW 2026

Obesity, Nutrition & Surgical Innovation (3/4)



Date	Title
03 May 2026	<u>CORRELATION OF VIBRATION-CONTROLLED TRANSIENT ELASTOGRAPHY WITH LIVER IMAGING FINDINGS IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE IN AN URBAN, PUBLIC SAFETY-NET HOSPITAL</u>
03 May 2026	<u>RACIAL AND SOCIOECONOMIC DISPARITIES IN ACCESS TO ADVANCED THERAPIES FOR METABOLIC STEATOHEPATITIS: A RANDOM-EFFECTS META-ANALYSIS OF U.S. AND INTERNATIONAL COHORTS</u>
03 May 2026	<u>FIRST META-ANALYSIS COMPARING LONG-TERM WEIGHT LOSS AND SAFETY BETWEEN ENDOSCOPIC SLEEVE GASTROPLASTY AND LAPAROSCOPIC SLEEVE GASTRECTOMY</u>
03 May 2026	<u>ENDOSCOPIC SLEEVE GASTRECTOMY (ESG) HAS COMPARABLE WEIGHT LOSS EFFICACY AND SAFETY TO GLP-1 RECEPTOR AGONISTS: RESULTS FROM A 52-WEEK RANDOM-EFFECTS NETWORK META-ANALYSIS</u>
03 May 2026	<u>EFFICACY OF COMBINING PRIMARY ENDOSCOPIC BARIATRIC AND METABOLIC THERAPIES WITH ANTI-OBESITY MEDICATIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS</u>
03 May 2026	<u>ECONOMIC EVALUATION OF PROXIMAL INTESTINAL MUCOSAL ABLATION IN INSULIN-REQUIRING TYPE 2 DIABETES: COST-EFFECTIVENESS AND PRICE THRESHOLD ANALYSIS FROM A US HEALTHCARE PAYER WITH COMPARISON TO SEMAGLUTIDE</u>
03 May 2026	<u>THE EFFICACY-EFFECTIVENESS GAP IN OBESITY MANAGEMENT: A META-ANALYSIS OF THE BIDIRECTIONAL DIVERGENCE BETWEEN BARIATRIC ENDOSCOPY AND ANTI-OBESITY MEDICATIONS</u>
03 May 2026	<u>NETWORK META-ANALYSIS OF PROCEDURAL INTERVENTIONS FOR WEIGHT REGAIN AFTER ROUX-EN-Y GASTRIC BYPASS: COMBINATION APPROACHES DEMONSTRATE SUPERIOR EFFICACY</u>



Notable Presentations Information At DDW 2026

Obesity, Nutrition & Surgical Innovation (4/4)



Date	Title
03 May 2026	<u>COMPARATIVE EFFECTIVENESS OF ENDOSCOPIC AND SURGICAL INTERVENTIONS FOR POST-RYGB WEIGHT REGAIN: NETWORK META-ANALYSIS WITH META-REGRESSION, AND SAFETY ANALYSIS.</u>
03 May 2026	<u>MANAGEMENT OF HIGH-RISK STIGMATA-POSITIVE INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM: A RETROSPECTIVE COMPARISON OF SURGICAL AND CONSERVATIVE APPROACHES</u>
03 May 2026	<u>RETROSPECTIVE ANALYSIS OF DETERMINANTS OF BOWEL PREPARATION QUALITY: A COMPARISON OF ORAL SULFATE SOLUTION AND POLYETHYLENE GLYCOL ELECTROLYTES</u>
03 May 2026	<u>CONTINENT ILEOSTOMY FOR FAMILIAL ADENOMATOUS POLYPOSIS: LONG-TERM RESULTS FROM A QUATERNARY CARE INSTITUTION</u>
03 May 2026	<u>PRESERVING SAFETY IN DIFFICULT CHOLECYSTECTOMY: OUTCOMES OF ROBOTIC COMPLETION SURGERY AT A TERTIARY HEPATOBILIARY CENTER</u>



Key Industry Sponsored Sessions Information



DDW 2026 Key Industry Sponsored Sessions Information (1/6)

Date	Title
01 May 2026	What You Need to Know About the Management of Short Bowel Syndrome and Intestinal Failure
02 May 2026	Revisiting Topical Therapies in UC: A Case-based Approach
02 May 2026	Cutting-Edge Updates in the Diagnosis and Treatment of Eosinophilic Esophagitis: Exploring Epithelial Cytokines and Their Therapeutic Implications
02 May 2026	PBC in Practice: Real-World Case Challenges and Solutions
02 May 2026	Targeting TL1A in IBD to Treat Both Inflammation and Fibrosis — A Wheel of Knowledge Challenge!
03 May 2026	Navigating IBD and Obesity: Lived Experiences and Collaborative Solutions
03 May 2026	Beyond Inflammation: The Latest TL1A Pathway Insights and Clinical Advances





DDW 2026 Key Industry Sponsored Sessions Information (2/6)

Date	Title
03 May 2026	Identifying Appropriate Patients for VELSIPITY (etrasimod)
03 May 2026	Striving for Durable Outcomes in UC
03 May 2026	Pursuing Control in Crohn's and Ulcerative Colitis
03 May 2026	A New Era in EoE: Exploring Epithelial-Driven Inflammation From the Top
03 May 2026	KOL Perspectives on New TREMFYA® Data
03 May 2026	Reach for Treatment Goals Together
03 May 2026	At the Crossroads of Inflammation and Fibrosis in Inflammatory Bowel Disease: The Promise of TL1A Inhibition



DDW 2026 Key Industry Sponsored Sessions Information (3/6)

Date	Title
03 May 2026	HBV Live! A Deep Dive Into the Evolving Landscape of Hepatitis B Management
03 May 2026	Redefining IBD Beyond Inflammation: The Immuno-Fibrotic Paradigm and The Potential of TL1A Pathway Intervention
03 May 2026	Subcutaneous Therapies in IBD: Evidence, Patient Selection, and Practical Approaches to Optimizing Outcomes
03 May 2026	Clinical Decisions in the Management of IBD: A Patient Case Challenge
03 May 2026	The Journey Starts Now: Making Evidence Matter for Long-Term Outcomes in IBD
04 May 2026	Playing the Long Game: Improving Durable Control in IBD
04 May 2026	Acute Hepatic Porphyria: A Case-Based Patient Journey



DDW 2026 Key Industry Sponsored Sessions Information (4/6)

Date	Title
04 May 2026	Advancements in Endohepatology: Aplio i800 EUS System with 2D Shear Wave Elastography and Attenuation Imaging
04 May 2026	Beyond the Data: From Clinical Cases to Patient Perspectives
04 May 2026	Clinical Considerations for the Management of Overt Hepatic Encephalopathy
04 May 2026	Rezdiffra: Unlocking the Potential of a Liver-Directed Treatment
04 May 2026	IBS-C: Identifying and Managing the Symptoms
04 May 2026	Flexing Your Clinical Muscles: EoE Cases to Strengthen Diagnosis and Treatment in Real-World Scenarios
04 May 2026	Survey Says: Aligning Early Advanced IBD Therapy With Patient Priorities



DDW 2026 Key Industry Sponsored Sessions Information (5/6)

Date	Title
04 May 2026	The Next Frontier in IBD: Late-Stage Clinical Advances with Novel Therapeutic Pathways
04 May 2026	Breaking News in IBS-C: Real-World Expert Insights, Patient Voices, and Challenging Cases
04 May 2026	From Trial Endpoints to Clinical Impact: Exploring the Latest IL-23p19 Evidence
05 May 2026	Eosinophilic Esophagitis (EoE): Understanding the Disease and a Treatment Option for Your Patients
05 May 2026	Understanding Zymfentra(infliximab-dyyb) the Only FDA Approved Self-Administered Infliximab
05 May 2026	Empowering Care for Adult Patients with IBS-C
05 May 2026	Clinical Insights Into a First-in-Class Treatment for Primary Biliary Cholangitis (PBC)



DDW 2026 Key Industry Sponsored Sessions Information (6/6)



Date	Title
05 May 2026	Clinical Clues to Diagnosing EPI
05 May 2026	The Face of Barrett's Esophagus is Changing: Leveraging precision molecular risk stratification in clinical management of Barrett's esophagus



Noteworthy AI / ML Presentations at DDW 2026





Themes from key AI / ML Presentations at DDW 2026 (1/3)

- **DDW 2026 is expected to position AI/ML as a clinical enabler across gastroenterology and hepatology, advancing real-time endoscopic detection, high-accuracy cancer diagnosis (>99% in pancreatic imaging), precision risk prediction, and workflow automation into routine care**
- Check out the key AI / ML themes at DDW 2026 below:
 - **Pancreatic AI Imaging:**
 - EfficientNetB7, EfficientNetV2, ResNet50, and ResNet152 models are set to expand CT/MRI-based pancreatic cancer detection, with one ResNet152 study reporting >99% accuracy
 - **Endoscopy Quality Automation:**
 - AI models are expected to assess colonoscopy quality, bowel preparation, withdrawal time, adenoma yield, and upper GI quality indicators from videos and reports
 - **Colorectal Detection & Risk Scoring:**
 - AI-assisted colonoscopy studies, CAD systems, and EHR-embedded CRC risk scores are positioned to improve polyp detection, miss-rate reduction, and population-level screening



Themes from key AI / ML Presentations at DDW 2026 (2/3)

- **Barrett's & Esophageal Neoplasia:**

- AI meta-analyses, including 169 Barrett's neoplasia studies, are expected to support digital biopsy concepts and earlier esophageal cancer detection

- **IBD Precision Modeling:**

- Machine learning and multi-omics approaches are set to predict IBD onset, pediatric progression, Crohn's recurrence after surgery, and treatment response

- **Hepatology Risk Prediction:**

- AI models are expected to refine cirrhosis survival, SBP exclusion, alcoholic hepatitis prognosis through the AIMA score, and HCC treatment selection

- **LLMs in Clinical Decision-Making:**

- ChatGPT, OpenEvidence, and LLM-based multi-agent systems are set to be tested against guidelines, simulations, and 15-vignette surveillance tasks

- **Workflow & Documentation Burden:**

- Ambient listening AI, automated documentation triage, and AI-generated pathology explanations are expected to reduce provider workload while preserving clinical sensitivity



Themes from key AI / ML Presentations at DDW 2026 (3/3)

- **Explainability & Safety Governance:**

- Explainable AI frameworks, FDA SaMD discussions, and generative AI policy analyses are positioned to address transparency, safety, bias, and clinical accountability

- **Microbiome & Multi-Omics AI:**

- Machine learning is expected to integrate microbial, diet, spatial proteomic, transcriptomic, and exosomal data for Crohn's disease, FMT matching, and cholangiocarcinoma risk



Noteworthy AI / ML Presentations at DDW 2026

Notable Presentations At DDW 2026

AI / ML (1/23)



Date	Title
02 May 2026	<u>REAL-TIME CHOLANGIOSCOPY ARTIFICIAL INTELLIGENCE FOR THE CLASSIFICATION OF INDETERMINATE BILIARY STRICTURES</u>
02 May 2026	<u>A TALE OF TWO REALITIES: AN INTERPRETABLE MACHINE LEARNING DESCRIPTION OF GUIDELINE-CONCORDANT CARE IN PANCREATIC CANCER</u>
02 May 2026	<u>EXPLAINABLE MACHINE LEARNING MODEL PREDICTS 30-DAY UNPLANNED READMISSION AFTER ACUTE PANCREATITIS HOSPITALIZATION</u>
02 May 2026	<u>ARTIFICIAL INTELLIGENCE FOR PANCREATIC CYST DYSPLASIA GRADING IN ENDOSCOPIC ULTRASOUND: A MULTICENTER STUDY</u>
02 May 2026	<u>SPARK: A CROSS PLATFORM EFFICIENTNET B4 POWERED ARTIFICIAL INTELLIGENCE SYSTEM REVOLUTIONIZING ACCURATE CT BASED DETECTION OF PANCREATIC CANCER</u>
02 May 2026	<u>ARTIFICIAL INTELLIGENCE USING TRANSFORMER ARCHITECTURE ACCURATELY CLASSIFIES ESOPHAGEAL MOTILITY ON FLIP PANOMETRY</u>
02 May 2026	<u>ARTIFICIAL INTELLIGENCE REVOLUTIONIZES GASTROENTEROLOGY: EFFICIENTNETB7 ACHIEVES HIGH-ACCURACY DETECTION OF COLORECTAL CANCER ON HISTOLOGIC IMAGES</u>
02 May 2026	<u>STRATIFYING RISKS FOR NEOPLASTIC POLYP DEVELOPMENT USING MACHINE LEARNING MODELS ON VA HEALTH RECORDS</u>

Notable Presentations At DDW 2026

AI / ML (2/23)



Date	Title
02 May 2026	<u>A MACHINE LEARNING-BASED EXOSOMAL LIQUID BIOPSY ENABLES STRATIFICATION OF OCCULT METASTASIS RISK IN PATIENTS WITH INTRAHEPATIC CHOLANGIOCARCINOMA: THE EXOMIC STUDY</u>
02 May 2026	<u>EARLY DIAGNOSIS AND PREDICTION OF INFLAMMATORY BOWEL DISEASE USING ELECTRONIC HEALTH RECORDS DATA AND LONGITUDINAL DEEP LEARNING</u>
02 May 2026	<u>RAPID URBANISATION AND IBD PREVALENCE IN RURAL INDIA: INSIGHTS FROM A SATELLITE BASED DEEP LEARNING INDEX</u>
02 May 2026	<u>GENERATIVE ARTIFICIAL INTELLIGENCE POLICIES IN GASTROENTEROLOGY AND HEPATOLOGY JOURNALS AND SCIENTIFIC MEETINGS: AN EXPLORATORY ANALYSIS AND CALL FOR ACTION</u>
02 May 2026	<u>AUTOMATED DEEP LEARNING–BASED DETECTION IN ERCP CHOLANGIOGRAMS: DEVELOPMENT AND VALIDATION STUDY</u>
02 May 2026	<u>MACHINE LEARNING–BASED PREDICTIVE MORTALITY SCORING MODEL FOR PATIENTS HOSPITALIZED WITH DIVERTICULITIS</u>
02 May 2026	<u>MULTI-OMICS AND MACHINE LEARNING TO RISK-STRATIFY SUBTYPES OF DISEASE PROGRESSION AND TREATMENT RESPONSE IN PEDIATRIC INFLAMMATORY BOWEL DISEASE</u>
02 May 2026	<u>MACHINE LEARNING-BASED PREDICTION OF POSTOPERATIVE ENDOSCOPIC RECURRENCE AFTER SMALL BOWEL SURGERY IN CROHN’S DISEASE: A SUB-ANALYSIS OF J-PROSPECT STUDY</u>



Notable Presentations At DDW 2026

AI / ML (3/23)



Date	Title
02 May 2026	<u>ARTIFICIAL INTELLIGENCE, DEEP LEARNING AND MACHINE LEARNING MODELS FOR PREDICTING POST-ENDOSCOPIC SUBMUCOSAL DISSECTION BLEEDING: A SYSTEMATIC REVIEW</u>
02 May 2026	<u>ARTIFICIAL INTELLIGENCE–GUIDED DEPTH PREDICTION ALTERS TREATMENT DECISIONS IN EARLY GASTRIC CANCER</u>
02 May 2026	<u>ARTIFICIAL INTELLIGENCE–BASED GASTRIC CANCER RISK STRATIFICATION WITH SURROUNDING MUCOSAL IMAGE ANALYSIS: PERFORMANCE AND IMPACT ON PHYSICIAN BEHAVIOR</u>
02 May 2026	<u>MACHINE LEARNING PREDICTION OF TREATMENT PERSISTENCE IN ULCERATIVE COLITIS: DATA ON 9,671 PATIENTS FROM THE PERSISTENCE AUSTRALIAN NATIONAL IBD COHORT (PANIC5)</u>
02 May 2026	<u>MACHINE LEARNING IDENTIFIES PROTEO-TRANSCRIPTOMICS MODULES ASSOCIATED WITH FIBROGENESIS IN ADVANCE FIBROSIS IN A JAPANESE MASH COHORT</u>
02 May 2026	<u>REAL-TIME INTEGRATION OF DEEP LEARNING LIVER SEGMENTATION INTO AN OPEN-SOURCE POINT-OF-CARE ULTRASOUND VIEWER</u>
02 May 2026	<u>EARLY PANCREATIC CANCER DETECTION ON CT USING A DEEP LEARNING SYSTEM: EXPLAINABLE, ROBUST, AND GLOBALLY DEPLOYABLE DECISION SUPPORT</u>
02 May 2026	<u>A DEEP LEARNING ARCHITECTURE, EFFICIENTNETB7, POWERED UNIVERSALLY ACCESSIBLE, CROSS-PLATFORM ARTIFICIAL INTELLIGENCE APPLICATION FOR ACCURATE DETECTION OF MICROSATELLITE INSTABILITY IN GASTROINTESTINAL CANCERS USING HISTOPATHOLOGY</u>



Notable Presentations At DDW 2026

AI / ML (4/23)



Date	Title
02 May 2026	<u>PERFORMANCE OF MACHINE LEARNING MODELS FOR PREDICTING MORTALITY IN GASTROINTESTINAL BLEEDING: A SYSTEMATIC REVIEW AND META-ANALYSIS</u>
02 May 2026	<u>EARLY EMERGENCY DEPARTMENT MACHINE LEARNING MODEL PREDICTS ICU ADMISSION AND IN-HOSPITAL MORTALITY IN ACUTE LOWER GASTROINTESTINAL BLEEDING</u>
02 May 2026	<u>MACHINE LEARNING–GUIDED RISK STRATIFICATION FOR CLINICALLY SIGNIFICANT GASTROINTESTINAL BLEEDING IN MECHANICALLY VENTILATED INTENSIVE CARE UNIT PATIENTS</u>
02 May 2026	<u>EVALUATION OF A PERSONALIZED, SECURE ARTIFICIAL INTELLIGENCE BASED VIRTUAL ASSISTANT FOR OPTIMIZING PHYSICIAN WORKLOAD AND IMPROVING PATIENT-PROVIDER COMMUNICATION</u>
02 May 2026	<u>ACCURACY OF ARTIFICIAL INTELLIGENCE-GENERATED BILLING FOR INTERVENTIONAL ENDOSCOPY PROCEDURES</u>
02 May 2026	<u>REAL-TIME CUE-BASED DEEP LEARNING ASSISTANT FOR DEPRESSED (PARIS IIC AND IIA PLUS IIC) HIGH-RISK LESION SPOTTER</u>
02 May 2026	<u>A MULTI-KINGDOM MACHINE LEARNING MODEL TO DISTINGUISH CROHN’S DISEASE FROM ULCERATIVE COLITIS</u>
02 May 2026	<u>MACHINE LEARNING-DERIVED BLOOD GENE SIGNATURES ENABLE NON-INVASIVE STRATIFICATION OF ENDOSCOPIC DISEASE SEVERITY IN ULCERATIVE COLITIS</u>

Notable Presentations At DDW 2026

AI / ML (5/23)



Date	Title
02 May 2026	<u>INTEGRATING GENOMICS, MOLECULAR BIOMARKERS, AND ARTIFICIAL INTELLIGENCE FOR PRECISION IBD THERAPY</u>
02 May 2026	<u>ARTIFICIAL INTELLIGENCE IN PEDIATRIC ENDOSCOPY: PROMISE, PITFALLS AND PEDIATRIC-SPECIFIC NEEDS</u>
02 May 2026	<u>TARGETING PATIENTS WHO MOST BENEFIT FROM EARLY REGULAR DIET IN ACUTE PANCREATITIS: SECONDARY ANALYSIS OF RCT USING MACHINE LEARNING MODELS</u>
02 May 2026	<u>LARGE LANGUAGE MODEL-BASED MULTI-AGENT SYSTEM OUTPERFORMS MACHINE LEARNING IN SENSITIVITY FOR RISK ASSESSMENT OF UPPER GASTROINTESTINAL BLEEDING</u>
03 May 2026	<u>MACHINE LEARNING AND THE MICROBIOME</u>
03 May 2026	<u>MULTI-OMIC INTEGRATIONS USING MACHINE LEARNING</u>
03 May 2026	<u>BEYOND THE SCOPE: THE EVER-CHANGING ROLE OF ARTIFICIAL INTELLIGENCE PLATFORMS</u>
03 May 2026	<u>THE ROLE OF ARTIFICIAL INTELLIGENCE IN THE INNOVATIVE CARE OF CHRONIC LIVER DISEASES</u>

Notable Presentations At DDW 2026

AI / ML (6/23)



Date	Title
03 May 2026	<u>ARTIFICIAL INTELLIGENCE-DRIVEN DONOR-RECIPIENT GUT MICROBIOME MATCHING FOR OPTIMIZED FECAL MICROBIOTA TRANSPLANTATION</u>
03 May 2026	<u>DECODING THE AMAZON CANCER PARADOX: UNRAVELING WHY AN AMAZONIAN METROPOLIS EXHIBITS A HIGH GASTRIC BUT LOW COLORECTAL CANCER BURDEN COMPARED TO GLOBAL URBAN PEERS USING DIET INDICATORS AND CAUSAL MACHINE LEARNING</u>
03 May 2026	<u>ARTIFICIAL INTELLIGENCE-BASED PROGNOSTIC MODELS IN CHOLANGIOCARCINOMA: A SYSTEMATIC REVIEW OF IMAGING, PATHOMICS AND MULTIMODAL APPROACHES</u>
03 May 2026	<u>HIERARCHICAL RESNET152 DEEP LEARNING ACHIEVES >99% ACCURACY IN CT-BASED PANCREATIC CANCER DETECTION: ENABLING EARLY AND ACCESSIBLE DIAGNOSTIC DECISION-MAKING</u>
03 May 2026	<u>COLON NET: A UNIVERSALLY ACCESSIBLE EFFICIENTNETB4 DEEP LEARNING ARCHITECTURE FOR RELIABLE COLON CANCER DIAGNOSIS FROM HISTOPATHOLOGY</u>
03 May 2026	<u>TOWARD EQUITABLE MOLECULAR SUBTYPING: EFFICIENTNET-LITE, A DEEP LEARNING ARCHITECTURE POWERED MSI/MSS CLASSIFICATION IN GI CANCERS USING WHOLE-SLIDE DIGITAL HISTOPATHOLOGY IN A CROSS-PLATFORM APPLICATION</u>
03 May 2026	<u>ARTIFICIAL INTELLIGENCE FOR ANAL CANCER SCREENING: FIRST MULTICENTRIC VALIDATION OF AN INTEROPERABLE SYSTEM FOR SIMULTANEOUS DETECTION AND DIFFERENTIATION OF SQUAMOUS CELL PRECURSOR LESIONS</u>
03 May 2026	<u>AUTONOMOUS ROBOTIC COLONOSCOPE INSERTION VIA DEEP LEARNING LUMEN DETECTION AND BEHAVIOR MIMICRY</u>

Notable Presentations At DDW 2026

AI / ML (7/23)



Date	Title
03 May 2026	<u>FEASIBILITY OF DIFFERENTIATING SERRATED PATHWAY POLYPS (GCHP, MVHP AND SSL) BASED ON ENDOSCOPIC APPEARANCE USING DEEP LEARNING</u>
03 May 2026	<u>PERFORMANCE OF AN ARTIFICIAL INTELLIGENCE DERIVED EHR EMBEDDED COLORECTAL CANCER RISK SCORE FOR PREDICTING INCIDENT CRC AT THE POPULATION LEVEL: A LARGE HEALTH SYSTEM EXPERIENCE</u>
03 May 2026	<u>REAL-TIME COMPARISON OF ARTIFICIAL INTELLIGENCE-ASSISTED COLONOSCOPY AND TRADITIONAL COLONOSCOPY</u>
03 May 2026	<u>AUTOMATED QUALITY ASSESSMENT IN ENDOSCOPY: A MULTIMODAL DEEP LEARNING SYSTEM FOR BOWEL PREPARATION EVALUATION</u>
03 May 2026	<u>ARTIFICIAL INTELLIGENCE ASSISTED COLONOSCOPY CAN COMPENSATE FOR INADEQUATE BOWEL PREPARATION</u>
03 May 2026	<u>RESNEXT-POWERED ARTIFICIAL INTELLIGENCE FOR AUTOMATED MICROSATELLITE INSTABILITY DETECTION IN GASTROINTESTINAL CANCER HISTOPATHOLOGY: ADVANCING EQUITABLE PRECISION ONCOLOGY</u>
03 May 2026	<u>RESNEXT DEEP LEARNING ARCHITECTURE FOR HIGH-FIDELITY HISTOPATHOLOGICAL DETECTION OF COLON CANCER IN A UNIVERSALLY ACCESSIBLE AI SYSTEM</u>
03 May 2026	<u>MACHINE LEARNING DEMONSTRATES SUPERIOR MORTALITY PREDICTION COMPARED TO TRADITIONAL RISK SCORES IN ACUTE GASTROINTESTINAL BLEEDING: A SYSTEMATIC REVIEW AND META-ANALYSIS</u>

Notable Presentations At DDW 2026

AI / ML (8/23)



Date	Title
03 May 2026	<u>PREDICTING PROGRESSION OF GASTRIC PRECANCER WITH ARTIFICIAL INTELLIGENCE: A MACHINE LEARNING MODEL FOR RISK STRATIFICATION AND SURVEILLANCE TIMING</u>
03 May 2026	<u>DIAGNOSTIC UTILITY OF ARTIFICIAL INTELLIGENCE IN DETECTING ACTIVE H. PYLORI INFECTION STATUS FROM ENDOSCOPIC IMAGES: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS.</u>
03 May 2026	<u>ASSESSMENT OF MASLD RISK PERCEPTION BEFORE AND AFTER VIEWING AN ARTIFICIAL INTELLIGENCE VIDEO AS AN INNOVATIVE EDUCATIONAL TOOL</u>
03 May 2026	<u>NONINVASIVE PREDICTION OF CLINICALLY SIGNIFICANT PORTAL HYPERTENSION AND FIRST DECOMPENSATION IN COMPENSATED CIRRHOSIS USING MACHINE LEARNING ON ROUTINE LABORATORY AND ULTRASOUND DATA</u>
03 May 2026	<u>FIRST 48-HOUR DEEP LEARNING MODEL PREDICTING ACUTE-ON-CHRONIC LIVER FAILURE PROGRESSION IN ICU CIRRHOSIS</u>
03 May 2026	<u>MULTITASK MACHINE LEARNING MODEL TO PREDICT TRANSFUSION BURDEN, INTERVENTION, ICU ESCALATION, AND MORTALITY IN HOSPITALIZED PATIENTS WITH GASTROINTESTINAL BLEEDING</u>
03 May 2026	<u>PREDICTING PROGRESSION TO HIGH-GRADE HEPATIC ENCEPHALOPATHY AND INTUBATION IN CIRRHOTIC ICU PATIENTS USING AN EXPLAINABLE MACHINE LEARNING MODEL</u>
03 May 2026	<u>MACHINE LEARNING OUTPERFORMS CONVENTIONAL SCORING SYSTEMS FOR PREDICTING LIVER FUNCTION RECOVERY IN CHRONIC LIVER DISEASES</u>

Notable Presentations At DDW 2026

AI / ML (9/23)



Date	Title
03 May 2026	<u>UNSUPERVISED MACHINE LEARNING IDENTIFIES CARDIAC PHENOTYPES IN CIRRHOSIS: A PVCLD2 GROUP STUDY</u>
03 May 2026	<u>REAL-TIME ROBUST LIVER SEGMENTATION IN POINT-OF-CARE ULTRASOUND USING A FEATURE-DISCRIMINATIVE MULTI-BRANCH DEEP LEARNING FRAMEWORK</u>
03 May 2026	<u>MACHINE LEARNING DOUBLES DETECTION OF ADVANCED LIVER FIBROSIS COMPARED TO FIB-4 INDEX USING IDENTICAL CLINICAL PARAMETERS</u>
03 May 2026	<u>MACHINE LEARNING AND RADIOMICS-BASED ALGORITHMS FOR CHARACTERIZATION OF LIVER LESIONS ON CONTRAST-ENHANCED MULTIPHASIC MRI</u>
03 May 2026	<u>STEPPING UP PRECISION ONCOLOGY: ARTIFICIAL INTELLIGENCE DRIVEN RESNET34 FOR AUTOMATED MICROSATELLITE INSTABILITY DETECTION IN GASTROINTESTINAL CANCERS</u>
03 May 2026	<u>ARTIFICIAL INTELLIGENCE REDUCES CAPSULE READING TIME BY 88% AND MATCHES EXPERT IN DETECTING SMALL BOWEL VASCULAR LESIONS</u>
03 May 2026	<u>IMPACT OF DEEP LEARNING BARRETT'S ESOPHAGUS DYSPLASIA GRADE PREDICTION MODEL ON EXPERT GASTROINTESTINAL PATHOLOGIST DIAGNOSTIC CONFIDENCE</u>
03 May 2026	<u>DEVELOPMENT OF A ROBUST MACHINE LEARNING CLASSIFIER BASED ON EXTRACHROMOSOMAL CIRCULAR DNA (ECCDNA) MULTI-OMICS FEATURES FOR THE DIAGNOSIS OF MALIGNANT BILIARY STRICTURE</u>

Notable Presentations At DDW 2026

AI / ML (10/23)



Date	Title
03 May 2026	<u>MACHINE LEARNING-DRIVEN EXOSOMAL MICRORNA SIGNATURE FOR PREOPERATIVE STAGING AND NEOADJUVANT THERAPY GUIDANCE IN COLON CANCER</u>
03 May 2026	<u>MACHINE LEARNING–GUIDED SPLICING ISOFORM SIGNATURE FOR PERSONALIZED EVALUATION OF ADJUVANT CHEMOTHERAPY IN COLORECTAL CANCER: THE SPLICE STUDY</u>
03 May 2026	<u>FROM VISION TO COGNITION: INTRAOPERATIVE ARTIFICIAL INTELLIGENCE IN COLORECTAL SURGERY, A SYSTEMATIC REVIEW</u>
03 May 2026	<u>ARTIFICIAL INTELLIGENCE FOR ENDOSCOPIC ULTRASOUND: MULTICENTER MULTIDEVICE DETECTION AND DIFFERENTIATION OF SUBEPITHELIAL LESIONS</u>
03 May 2026	<u>MODELING INTESTINAL EPITHELIAL WOUND HEALING USING NOVEL MOUSE ORGANOID CULTURE SYSTEM COMBINED WITH ARTIFICIAL INTELLIGENCE (AI)-BASED IMAGE ANALYSIS</u>
03 May 2026	<u>LEVERAGING ROUTINE CT IMAGING TO IMPROVE OSTEOPOROSIS SCREENING IN PATIENTS WITH IBD: A DEEP LEARNING-BASED APPROACH TO OPPORTUNISTIC CT SCREENING</u>
03 May 2026	<u>MACHINE LEARNING IDENTIFIES HIDDEN HEPATIC FIBROSIS IN ADULTS WITH NORMAL FIB-4: A NHANES-BASED RISK-STRATIFICATION MODEL</u>
03 May 2026	<u>MACHINE LEARNING-ASSISTED GENETIC RISK SCORE FOR CALORIES TO SATIATION IS ASSOCIATED WITH HEPATIC STEATOSIS INDEPENDENT OF BMI</u>



Notable Presentations At DDW 2026

AI / ML (11/23)



Date	Title
03 May 2026	<u>IMPACT OF ARTIFICIAL INTELLIGENCE ON PATIENT PERCEPTIONS OF MASLD</u>
03 May 2026	<u>POPULATION-LEVEL EVALUATION OF THE SCORES FOR PREDICTING PANCREATIC CANCER RISK IN NEW ONSET DIABETES AND COMPARISON WITH MACHINE LEARNING</u>
03 May 2026	<u>MISSED PANCREATIC CANCER: DO WE UNDERSTAND THE CAUSES AND CAN WE PREVENT IT WITH ARTIFICIAL INTELLIGENCE?</u>
03 May 2026	<u>DETECTION OF LYMPH NODES AND MALIGNANCY PREDICTION APPLYING ARTIFICIAL INTELLIGENCE IN ENDOSCOPIC ULTRASOUND: A MULTICENTRIC STUDY</u>
03 May 2026	<u>ARTIFICIAL INTELLIGENCE: ITS CURRENT ROLE IN ADDRESSING HEALTH DISPARITIES</u>
03 May 2026	<u>ARTIFICIAL INTELLIGENCE IN PATIENT CARE: CAUTIONARY TALES AND LIMITATIONS</u>
04 May 2026	<u>ARTIFICIAL INTELLIGENCE FOR GI BLEEDING: TRANSCONTINENTAL MULTICENTER VALIDATION OF AUTOMATED VASCULAR AND HAEMATIC DETECTION IN CAPSULE ENDOSCOPY</u>
04 May 2026	<u>HUMAN INTERPRETATION VERSUS ARTIFICIAL INTELLIGENCE FOR SAFETY CLASSIFICATION OF ENDOSCOPIC ULTRASOUND-GUIDED GALLBLADDER DRAINAGE (EUS-GBD) WINDOWS: A CLINICAL TRIAL</u>

Notable Presentations At DDW 2026

AI / ML (12/23)



Date	Title
04 May 2026	<u>CONSTRUCTION AND EVALUATION OF A DEEP LEARNING MODEL FOR RAPID DIAGNOSIS OF HIGH-RESOLUTION ESOPHAGEAL MANOMETRY IMAGES</u>
04 May 2026	<u>ASSESSING THE UTILITY OF LARGE LANGUAGE MODEL-BASED ARTIFICIAL INTELLIGENCE IN AUGMENTING THE PREOPERATIVE TESTING PROCESS FOR PATIENTS UNDERGOING COLORECTAL SURGERY</u>
04 May 2026	<u>THE IMPACT OF AMBIENT LISTENING ARTIFICIAL INTELLIGENCE TECHNOLOGY ON THE ELECTRONIC HEALTH RECORD BURDEN OF OUTPATIENT GASTROENTEROLOGY PROVIDERS IN A LARGE TRI-STATE TERTIARY REFERRAL CENTER</u>
04 May 2026	<u>THE ROLE OF ARTIFICIAL INTELLIGENCE IN FLAT AND DIMINUTIVE COLORECTAL LESION DETECTION: A SYSTEMATIC REVIEW AND META-ANALYSIS</u>
04 May 2026	<u>ARTIFICIAL INTELLIGENCE CHATBOTS VS. PROFESSIONAL GUIDELINES IN ENDOSCOPIC SURVEILLANCE DECISION-MAKING: A 15-VIGNETTE EVALUATION</u>
04 May 2026	<u>A PROSPECTIVE MULTICENTER RANDOMIZED CONTROLLED TRIAL OF THE USE OF REAL TIME ARTIFICIAL INTELLIGENCE FOR POLYPS DETECTION, IN A WESTERN POPULATION: CAN ENDOSCOPIST EXPERIENCE MAKE A DIFFERENCE?</u>
04 May 2026	<u>DEVELOPMENT AND VALIDATION OF A MACHINE LEARNING-BASED EARLY RISK STRATIFICATION MODEL FOR ACUTE UPPER GASTROINTESTINAL BLEEDING</u>
04 May 2026	<u>ARTIFICIAL INTELLIGENCE–ASSISTED COLONOSCOPY IMPROVES ADENOMA DETECTION AND REDUCES MISS RATE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS</u>

Notable Presentations At DDW 2026

AI / ML (13/23)



Date	Title
04 May 2026	<u>OBJECTIVE AND CONTINUOUS ASSESSMENT OF BOWEL PREPARATION QUALITY USING DEEP LEARNING-BASED SCENE SEGMENTATION</u>
04 May 2026	<u>IMPLEMENTATION OF A FAIR-COMPLIANT VIDEO DATABANK FOR ARTIFICIAL INTELLIGENCE MODEL DEVELOPMENT AND CLINICAL OUTCOMES RESEARCH IN GASTROINTESTINAL ENDOSCOPY</u>
04 May 2026	<u>IS ARTIFICIAL INTELLIGENCE IN COLONOSCOPY WORTH THE TIME? A SECONDARY META-ANALYSIS OF WITHDRAWAL TIME, ADENOMA YIELD, AND PROCEDURAL EFFICIENCY</u>
04 May 2026	<u>PREDICTING TROUBLE BEFORE IT STRIKES: MACHINE LEARNING MODELS FOR POST-ERCP OUTCOMES IN MALIGNANT BILIARY OBSTRUCTION - A SYSTEMATIC REVIEW</u>
04 May 2026	<u>SPATIOTEMPORAL DEEP LEARNING FRAMEWORK FOR VIDEO-BASED ABNORMALITY DETECTION IN MAGNIFICATION ENDOSCOPY USING 3D CONVOLUTIONS AND TEMPORAL ATTENTION</u>
04 May 2026	<u>ARTIFICIAL INTELLIGENCE FOR REAL-TIME HISTOLOGIC PREDICTION OF COLORECTAL POLYPS: SYSTEMATIC REVIEW AND META-ANALYSIS</u>
04 May 2026	<u>MACHINE LEARNING PREDICTION OF EARLY RESCUE TIPS OR BALLOON TAMPONADE AFTER ACUTE VARICEAL HEMORRHAGE IN ICU PATIENTS</u>
04 May 2026	<u>DEEP LEARNING BASED VGG19 MODEL FOR AUTOMATED DETECTION OF GASTROESOPHAGEAL REFLUX DISEASE IN ENDOSCOPIC IMAGES: PERFORMANCE, CALIBRATION AND EXPLAINABILITY ANALYSIS</u>

Notable Presentations At DDW 2026

AI / ML (14/23)



Date	Title
04 May 2026	<u>DIAGNOSTIC ACCURACY OF ARTIFICIAL INTELLIGENCE VERSUS EXPERT ENDOSCOPISTS FOR DETECTING ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS</u>
04 May 2026	<u>DIAGNOSTIC ACCURACY OF ARTIFICIAL INTELLIGENCE FOR EARLY DETECTION OF BARRETT'S NEOPLASIA: A COMPREHENSIVE SYSTEMATIC REVIEW AND META-ANALYSIS OF 169 STUDIES</u>
04 May 2026	<u>ARE DIGITAL BIOPSIES THE FUTURE? A SYSTEMATIC REVIEW AND META-ANALYSIS ASSESSING THE CLINICAL POTENTIAL OF ARTIFICIAL INTELLIGENCE (AI) MODELS IN DETECTING EARLY NEOPLASIA ASSOCIATED WITH BARRETT'S ESOPHAGUS</u>
04 May 2026	<u>MACHINE LEARNING PREDICTION OF INFECTED PANCREATIC NECROSIS AND NEED FOR INVASIVE INTERVENTION IN SEVERE ACUTE PANCREATITIS REQUIRING ICU CARE</u>
04 May 2026	<u>ARTIFICIAL INTELLIGENCE FOR AUTOMATED DETECTION AND CLASSIFICATION OF PANCREATIC CYSTS FROM ENDOSCOPIC ULTRASOUND (EUS) VIDEOS</u>
04 May 2026	<u>EUSOMICA ENHANCES THE PREDICTION OF HIGH-GRADE DYSPLASIA/INVASIVE CANCER IN IPMN BEYOND KYOTO GUIDELINES: AN EUSOMIC-CLINICAL MACHINE LEARNING STUDY</u>
04 May 2026	<u>ACUTE PANCREATITIS OUTCOME PREDICTION WITH DEEP LEARNING AND RADIOMICS</u>
04 May 2026	<u>ACCURATE DETECTION OF PANCREATIC CANCER ON CT USING EFFICIENTNETB7: A CROSS-PLATFORM DEEP LEARNING APPLICATION FOR EQUITABLE CANCER CARE</u>

Notable Presentations At DDW 2026

AI / ML (15/23)



Date	Title
04 May 2026	<u>EFFICIENTNET-LITE, A NOVEL DEEP LEARNING ARCHITECTURE, FOR ACCURATE DETECTION OF PANCREATIC CANCERS USING COMPUTERIZED TOMOGRAPHY: A STEP TOWARDS EQUITABLE CANCER CARE</u>
04 May 2026	<u>DEEP LEARNING–DRIVEN CT DIAGNOSIS OF PANCREATIC CANCER WITH EFFICIENTNETV2: A CROSS-PLATFORM AI APPROACH FOR EQUITABLE CARE</u>
04 May 2026	<u>UNIVERSALLY ACCESSIBLE AI FOR PANCREATIC CANCER DETECTION: A RESNET50-POWERED, CROSS-PLATFORM DEEP LEARNING SYSTEM USING CT IMAGING.</u>
04 May 2026	<u>DIAGNOSTIC ACCURACY OF ARTIFICIAL INTELLIGENCE MODELS FOR PANCREATIC CANCER DETECTION ON MAGNETIC RESONANCE IMAGING: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS</u>
04 May 2026	<u>AN ARTIFICIAL INTELLIGENCE-BASED PROGNOSTIC MODEL FOR ALCOHOLIC HEPATITIS IN A HISPANIC POPULATION: THE AIMAH SCORE</u>
04 May 2026	<u>DEVELOPMENT OF A MACHINE LEARNING MODEL FOR PREDICTION OF LATE SURVEILLANCE FOLLOWING SUCCESSFUL ERADICATION OF BARRETT’S ESOPHAGUS-RELATED NEOPLASIA</u>
04 May 2026	<u>PREDICTING HIGH-RISK COLORECTAL POLYPS USING PRE-COLONOSCOPY FEATURES: MACHINE LEARNING MODEL DEVELOPMENT AND VALIDATION</u>
04 May 2026	<u>ARTIFICIAL INTELLIGENCE AND ENDOANAL ULTRASOUND: MULTICENTER VALIDATION OF AUTOMATED DETECTION AND DIFFERENTIATION OF BENIGN LESIONS</u>

Notable Presentations At DDW 2026

AI / ML (16/23)



Date	Title
04 May 2026	<u>ARTIFICIAL INTELLIGENCE-BASED DIETARY PATTERN RECOGNITION AND ITS ASSOCIATION WITH GUT-RELATED SYMPTOMS AND METABOLIC HEALTH IN OBESE PAKISTANI POPULATION</u>
04 May 2026	<u>A MACHINE LEARNING MODEL TO PREDICT RESPONSE TO RADIOLIGAND THERAPY IN PATIENTS WITH ADVANCED GASTROENTEROPANCREATIC NEUROENDOCRINE NEOPLASMS PROGRESSIVE AFTER SOMATOSTATIN ANALOGS</u>
04 May 2026	<u>DECODING CELLULAR CROSSTALK IN INFLAMMATORY BOWEL DISEASE THROUGH DEEP LEARNING-DRIVEN SPATIAL PROTEOMIC AND TRANSCRIPTOMIC MAPPING</u>
04 May 2026	<u>VALIDATION OF A MACHINE LEARNING MODEL TO NON-INVASIVELY EXCLUDE SBP</u>
04 May 2026	<u>PREDICTING THE BEST POTENTIAL TREATMENT BY ARTIFICIAL INTELLIGENCE FOR PATIENTS AFFECTED BY HEPATOCELLULAR CARCINOMA: DEVELOPING AN AUGMENTED-MULTIDISCIPLINARY TUMOR BOARD.</u>
04 May 2026	<u>EXPLAINABLE MACHINE LEARNING MODEL TO PREDICT 90-DAY TRANSPLANT-FREE SURVIVAL IN HOSPITALIZED PATIENTS WITH CIRRHOSIS: A MIMIC-IV ANALYSIS</u>
04 May 2026	<u>ARTIFICIAL INTELLIGENCE ACCURATELY MEASURES PHYSICIAN COLONOSCOPY QUALITY METRICS FROM RECORDED COLONOSCOPY VIDEOS</u>
04 May 2026	<u>DEVELOPMENT AND VALIDATION OF ARTIFICIAL INTELLIGENCE MODEL FOR THE ASSESSMENT OF UPPER GASTROINTESTINAL ENDOSCOPY QUALITY INDICATORS BASED ON ANALYSIS OF ENDOSCOPY REPORTS.</u>

Notable Presentations At DDW 2026

AI / ML (17/23)



Date	Title
04 May 2026	<u>MACHINE LEARNING-DRIVEN INTEGRATED ANALYSIS OF MULTINATIONAL MICROBIAL, DIET AND CLINICAL DATA IDENTIFIES THE DETERMINANTS OF CROHN'S DISEASE. THE ENIGMA STUDY</u>
04 May 2026	<u>INTERPRETABLE MACHINE LEARNING TO IDENTIFY GERMLINE GENETIC MARKERS OF COLITIS-ASSOCIATED COLORECTAL CANCER RISK</u>
04 May 2026	<u>A NEW ARTIFICIAL INTELLIGENCE-ASSISTED DESIGNED DRUG REDUCES INTESTINAL FIBROSIS VIA SPHINGOSINE-1-PHOSPHATE RECEPTOR 3-DEPENDENT INHIBITION OF GRANULOCYTE-COLONY STIMULATING FACTOR EXPRESSION.</u>
04 May 2026	<u>REAL-TIME ARTIFICIAL INTELLIGENCE IN POSITIVE FECAL IMMUNOCHEMICAL TEST SCREENING COLONOSCOPY: COMPARABLE DETECTION PERFORMANCE BUT ENHANCED OPTICAL DIAGNOSIS IN A RANDOMIZED CLINICAL TRIAL</u>
04 May 2026	<u>COMBINATION OF ARTIFICIAL INTELLIGENCE AND MUCOSAL EXPOSURE DEVICE TO ENHANCE ADENOMA DETECTION IN COLONOSCOPY: A MULTICENTER RANDOMIZED CONTROLLED TRIAL</u>
04 May 2026	<u>A NATIONWIDE STUDY OF ARTIFICIAL INTELLIGENCE IN ADENOMA DETECTION DURING COLONOSCOPY - RESULT FROM THE NAIAD TRIAL</u>
04 May 2026	<u>MACHINE LEARNING-DRIVEN RAMAN SPECTROSCOPY, VALIDATED BY METABOLOMICS, IDENTIFIES NOVEL NON-INVASIVE BIOMARKERS OF BARRIER INTEGRITY AND OUTCOMES IN INFLAMMATORY BOWEL DISEASE</u>
04 May 2026	<u>DEEP LEARNING RADIOMICS DECODES HIDDEN SUBTYPES OF HEPATOCELLULAR CARCINOMA AND PREDICTS RECURRENCE RISK BEYOND VISUAL MORPHOLOGY</u>

Notable Presentations At DDW 2026

AI / ML (18/23)



Date	Title
04 May 2026	<u>SIMPLE DEEP LEARNING TRIAGE REDUCES ENDOSCOPIC DOCUMENTATION BURDEN WHILE PRESERVING LESION SENSITIVITY</u>
04 May 2026	<u>APPLICATION OF ARTIFICIAL INTELLIGENCE CADE TO IMPROVE POLYP DETECTION AND READING TIME IN COLON CAPSULE ENDOSCOPY (CCE)</u>
04 May 2026	<u>ACCURATE POLYP SIZE MEASUREMENT WITH ARTIFICIAL INTELLIGENCE AS THE NEW REFERENCE STANDARD</u>
04 May 2026	<u>COMPARATIVE PERFORMANCE OF ARTIFICIAL INTELLIGENCE-BASED COMPUTER-AIDED DETECTION SYSTEMS FOR COLORECTAL POLYPS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS</u>
04 May 2026	<u>DEVELOPMENT OF AN ARTIFICIAL INTELLIGENCE MODEL FOR PREDICTING URGENT COLONOSCOPY FINDINGS USING MULTIMODAL CLINICAL DATA</u>
04 May 2026	<u>A MULTI-METHOD EXPLAINABILITY FRAMEWORK FOR REAL-TIME ARTIFICIAL INTELLIGENCE SEGMENTATION IN PANCREATIC ENDOSCOPIC ULTRASOUND</u>
04 May 2026	<u>EXPLAINABLE DEEP LEARNING FRAMEWORK FOR ATTRIBUTION-GUIDED INTERPRETATION OF MICROVASCULAR CLASSIFICATION IN MAGNIFICATION ENDOSCOPY</u>
05 May 2026	<u>REAL-TIME EDGE-FOCUSED DEEP LEARNING ASSISTANT FOR POST-POLYPECTOMY MARGIN ASSESSMENT</u>

Notable Presentations At DDW 2026

AI / ML (19/23)



Date	Title
05 May 2026	<u>MULTIMODAL MACHINE LEARNING MODEL PREDICTS 6-WEEK OUTCOMES AFTER ACUTE VARICEAL HEMORRHAGE USING STRUCTURED DATA AND ENDOSCOPY TEXT</u>
05 May 2026	<u>MACHINE LEARNING ALGORITHM IDENTIFIES SUPRAGASTRIC BELCHING WITH EXCELLENT SENSITIVITY AND ACCURACY IN A POPULATION OF REFLUX PATIENTS TESTED WITH PH IMPEDANCE MONITORING</u>
05 May 2026	<u>AN ARTIFICIAL INTELLIGENCE MODEL TO PREDICT THE EFFICACY OF ACID-SUPPRESSIVE THERAPY IN PATIENTS WITH TYPICAL OR ATYPICAL GASTROESOPHAGEAL REFLUX SYMPTOMS</u>
05 May 2026	<u>DEVELOPMENT OF A DEEP LEARNING PROGRESSION RISK PREDICTION MODEL INCORPORATING DIGITIZED BARRETT'S ESOPHAGUS HISTOPATHOLOGY SLIDES</u>
05 May 2026	<u>COMBINING MACHINE LEARNING WITH PLASMA PROTEOMICS IN POPULATION AND CLINICAL COHORTS IDENTIFY REG4 AS A BIOMARKER FOR EARLY ESOPHAGEAL CANCER DETECTION</u>
05 May 2026	<u>SELF-SUPERVISED DEEP LEARNING ACHIEVES HIGH-ACCURACY GRADING OF DYSPLASIA IN BARRETT'S ESOPHAGUS</u>
05 May 2026	<u>DISTENSION AND CONTRACTION PHASES OF PERISTALSIS: WHICH IS BETTER IN DIAGNOSING ESOPHAGEAL MOTOR DISORDERS? DEEP LEARNING ENABLED ARTIFICIAL INTELLIGENCE ANALYSIS</u>
05 May 2026	<u>INTRAOPERATIVE CHOLANGIOSCOPY ENHANCED BY ARTIFICIAL INTELLIGENCE FOR MARGIN ASSESSMENT IN INTRADUCTAL PAPILLARY NEOPLASM OF THE BILE DUCT: A FEASIBILITY CASE REPORT</u>

Notable Presentations At DDW 2026

AI / ML (20/23)



Date	Title
05 May 2026	<u>MULTIMODAL DEEP LEARNING SYSTEM FOR AUTOMATED CHICAGO CLASSIFICATION USING HIGH-RESOLUTION MANOMETRY IMAGING AND TIME-SERIES DYNAMICS</u>
05 May 2026	<u>MULTIMODAL MACHINE LEARNING PIPELINE FOR PREDICTING THERAPEUTIC OUTCOMES USING HIGH-RESOLUTION MANOMETRY, FLIP METRICS, AND LONGITUDINAL MOTILITY DATA</u>
05 May 2026	<u>ARTIFICIAL INTELLIGENCE AND FLIP PANOMETRY: AUTOMATIC CHARACTERIZATION OF MOTILITY PATTERNS UNDER THE DALLAS CONSENSUS</u>
05 May 2026	<u>ARTIFICIAL INTELLIGENCE MODELS DEMONSTRATE PROMISING BUT SUBOPTIMAL PERFORMANCE IN DIAGNOSING AND TREATING DISORDERS OF GUT-BRAIN INTERACTION</u>
05 May 2026	<u>MACHINE LEARNING ENABLES DEEP IMMUNOPHENOTYPING OF INFLAMMATORY BOWEL DISEASE USING SINGLE-CELL TRANSCRIPTOMIC AND IMMUNE REPERTOIRE SIGNATURES IN PERIPHERAL BLOOD MONONUCLEAR CELLS</u>
05 May 2026	<u>MACHINE LEARNING-BASED STRATIFICATION TO DEFINE DISTINCT DISEASE TRAJECTORIES FOLLOWING ADVANCED THERAPY INITIATION IN CROHN'S DISEASE AND ULCERATIVE COLITIS</u>
05 May 2026	<u>UNSUPERVISED MACHINE LEARNING TO IDENTIFY DISTINCT CDAI-BASED RESPONSE PATTERNS TO GUSELKUMAB IN PARTICIPANTS WITH CROHN'S DISEASE: POST HOC ANALYSIS OF THE POOLED GRAVITI AND GALAXI 2/3 STUDIES</u>
05 May 2026	<u>PREDICTING THE CLINICAL COURSE OF NEWLY DIAGNOSED ULCERATIVE COLITIS PATIENTS: A NATIONWIDE MACHINE LEARNING MODEL WITH EXTERNAL VALIDATION IN A MULTI-CENTER EUROPEAN INCEPTION COHORT</u>

Notable Presentations At DDW 2026

AI / ML (21/23)



Date	Title
05 May 2026	<u>REDEFINING TREAT-TO-TARGET IN CROHN'S DISEASE: A PAN-INTESTINAL, MULTIDEVICE DEEP LEARNING MODEL FOR THE DETECTION AND DIFFERENTIATION OF ULCERS AND EROSIONS IN CAPSULE ENDOSCOPY</u>
05 May 2026	<u>MACHINE LEARNING-BASED EARLY PREDICTION OF IN-HOSPITAL COLECTOMY IN SEVERE ULCERATIVE COLITIS</u>
05 May 2026	<u>TRANSFORMER-BASED TIME-AWARE ARTIFICIAL INTELLIGENCE MODEL FOR PREDICTING CROHN'S DISEASE PROGRESSION IN MULTICENTER LONGITUDINAL COHORTS</u>
05 May 2026	<u>ARTIFICIAL INTELLIGENCE FOR DETECTION OF SMALL BOWEL EROSIONS AND ULCERS IN CAPSULE ENDOSCOPY: REAL-WORLD EVIDENCE FROM A MULTICENTRIC TRANSCONTINENTAL PROSPECTIVE STUDY</u>
05 May 2026	<u>THE APPLICATION OF AN ARTIFICIAL INTELLIGENCE-POWERED VIRTUAL REALITY COGNITIVE-BEHAVIORAL THERAPY TOOL FOR PAIN AND ANXIETY IN INFLAMMATORY BOWEL DISEASE POPULATIONS: A MULTI-SITE MULTI-METHOD PILOT STUDY</u>
05 May 2026	<u>IDENTIFYING THE CLINICAL ETIOLOGY AND PROGNOSTIC FACTORS OF CROHN'S DISEASE USING MACHINE LEARNING IN JAPANESE NATIONAL DATABASE</u>
05 May 2026	<u>FOOD FOR ARTIFICIAL INTELLIGENCE'S THOUGHTS? ASSESSING DIFFERENCES IN LARGE LANGUAGE MODEL GENERATED DIETARY RECOMMENDATIONS</u>
05 May 2026	<u>GASTROENTEROLOGIST AND ARTIFICIAL INTELLIGENCE INTERPRETATION OF ENDOSCOPIC CRITERIA FOR METABOLIC DUODENOPATHY: A PILOT VALIDATION STUDY</u>

Notable Presentations At DDW 2026

AI / ML (22/23)



Date	Title
05 May 2026	<u>REAL-TIME ARTIFICIAL INTELLIGENCE-DRIVEN FEEDBACK SYSTEM FOR OPTIMIZING ENDOSCOPIC IMAGE QUALITY</u>
05 May 2026	<u>LABEL-FREE PROFILING OF LIVER CELL TYPE DIVERSITY AND MACHINE LEARNING REVEALS TOX+CD8+ CELLS ARE SUFFICIENT TO DISTINGUISH AUTOIMMUNE HEPATITIS FROM DISEASE CONTROLS</u>
05 May 2026	<u>DIAGNOSTIC UTILITY OF ARTIFICIAL INTELLIGENCE IN DETECTING H. PYLORI IN GASTRIC BIOPSY WITH HISTOPATHOLOGY: A SYSTEMATIC REVIEW AND META-ANALYSIS</u>
05 May 2026	<u>A MACHINE LEARNING-INFORMED TSRNA-BASED LIQUID BIOPSY ASSAY FOR EARLY DETECTION OF HEPATOCELLULAR CARCINOMA: THE CENTINEL STUDY</u>
05 May 2026	<u>ARTIFICIAL INTELLIGENCE-ASSISTED DETECTIVE FLOW IMAGING ENABLES OBJECTIVE MICROVASCULAR QUANTIFICATION IN HEALTHY AND PATHOLOGIC LIVER DURING ENDOSCOPIC ULTRASOUND</u>
05 May 2026	<u>ARTIFICIAL INTELLIGENCE–BASED QFIBROSIS WITH SECOND HARMONIC GENERATION UNCOVERS DISTINCT LAYER-SPECIFIC COLLAGEN ARCHITECTURE IN CROHN’S DISEASE BIOPSIES</u>
05 May 2026	<u>GENERALIZABILITY OF A SYMPTOM-BASED ELECTRONIC HEALTH RECORD MACHINE LEARNING MODEL FOR ACUTE GASTROINTESTINAL BLEEDING ACROSS HEALTH SYSTEMS</u>
05 May 2026	<u>MULTICENTER ARTIFICIAL INTELLIGENCE-BASED AUTOMATED PHASE RECOGNITION IN PERORAL ENDOSCOPIC MYOTOMY USING DEEP IMAGE EMBEDDINGS: A HIGH-ACCURACY MODEL FOR PROCEDURAL ASSESSMENT</u>

Notable Presentations At DDW 2026

AI / ML (23/23)



Date	Title
05 May 2026	<u>PERFORMANCE OF A MACHINE LEARNING–ASSISTED GENE RISK SCORE FOR CALORIES-TO-SATIATION TO PREDICT WEIGHT LOSS AFTER SLEEVE GASTRECTOMY: 8-YEAR EXPERIENCE</u>
05 May 2026	<u>ARTIFICIAL INTELLIGENCE IMPROVES ADENOMA DETECTION WITHOUT PROLONGING WITHDRAWAL TIME: RESULTS OF A MULTICENTER RANDOMIZED TRIAL.</u>

Strategic Insights and Strategy Development is our focus



COMPETITIVE STRATEGY
AND INTELLIGENCE



DIGITAL HEALTH, ARTIFICIAL
INTELLIGENCE AND IoE



GENE & CELL THERAPY



VACCINES & INFECTIOUS
DISEASES



INVESTMENT INSIGHTS

e: INFO@LQVENTURES.COM

w: WWW.LQVENTURES.COM